<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2410222786
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2006
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        XOLAIR 150MG Powder for injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OMALIZUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        150
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        powder for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1796.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVARTIS Pharma Stein AG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVARTIS Pharma Stein AG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVARTIS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03DX05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Xolair contains the active substance omalizumab. Omalizumab is a man-made protein that is similar to natural proteins produced by the body. It belongs to a class of medicines called monoclonal antibodies.</p><p>&nbsp;</p><p>Xolair is used for the treatment of:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic asthma</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chronic rhinosinusitis (inflammation of the nose and sinuses) with nasal polyps</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chronic spontaneous urticaria (CSU)</p><p>&nbsp;</p><p><u>Allergic asthma</u></p><p>This medicine is used to prevent asthma from getting worse by controlling symptoms of severe allergic asthma in adults, adolescents and children (6&nbsp;years of age and older) who are already receiving asthma medicine, but whose asthma symptoms are not well controlled by medicines such as high-dose steroid inhalers and beta-agonist inhalers.</p><p>&nbsp;</p><p><u>Chronic rhinosinusitis with nasal polyps</u></p><p>This medicine is used to treat chronic rhinosinusitis with nasal polyps in adults (18&nbsp;years of age and older) who are already receiving intranasal corticosteroids (corticosteroid nasal spray), but whose symptoms are not well controlled by these medicines. Nasal polyps are small growths on the lining of the nose. Xolair helps to reduce the size of the polyps and improves symptoms including nasal congestion, loss of sense of smell, mucus in the back of the throat and runny nose.</p><p>&nbsp;</p><p><u>Chronic spontaneous urticaria (CSU)</u></p><p>This medicine is used to treat chronic spontaneous urticaria in adults and adolescents (12&nbsp;years of age and older) who are already receiving antihistamines but whose CSU symptoms are not well controlled by these medicines.</p><p>&nbsp;</p><p>Xolair works by blocking a substance called immunoglobulin E (IgE), which is produced by the body. IgE contributes to a type of inflammation that plays a key role in causing allergic asthma, chronic rhinosinusitis with nasal polyps and CSU.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a. Do not take Xolair:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to omalizumab or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>If you think you may be allergic to any of the ingredients, tell your doctor as you should not be given Xolair.</p><p>&nbsp;</p><p><strong>b. Take special care with Xolair</strong></p><p>Talk to your doctor before you use Xolair:</p><p><s>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </s>if you have kidney or liver problems.</p><p><s>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </s>if you have a disorder where your own immune system attacks parts of your own body (autoimmune disease).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are travelling to a region where infections caused by parasites are common ‑ Xolair may weaken your resistance to such infections.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had a previous severe allergic reaction (anaphylaxis) for example resulting from a medicine, an insect bite or food.</p><p>&nbsp;</p><p>Xolair does not treat acute asthma symptoms, such as a sudden asthma attack. Therefore Xolair should not be used to treat such symptoms.</p><p>&nbsp;</p><p>Xolair is not meant to prevent or treat other allergy-type conditions, such as sudden allergic reactions, hyperimmunoglobulin E syndrome (an inherited immune disorder), aspergillosis (a fungus-related lung disease), food allergy, eczema or hay fever because Xolair has not been studied in these conditions.</p><p>&nbsp;</p><p><strong>Look out for signs of allergic reactions and other serious side effects</strong></p><p>Xolair can potentially cause serious side effects. You must look out for signs of these conditions while you use Xolair. Seek medical help immediately if you notice any signs indicating a possible serious side effect. Such signs are listed under &ldquo;Serious side effects&rdquo; in section&nbsp;4. The majority of severe allergic reactions occur within the first 3&nbsp;doses of Xolair.</p><p>&nbsp;</p><p><strong>c. Children and adolescents</strong></p><p><u>Allergic asthma</u></p><p>Xolair is not recommended for children under 6&nbsp;years of age. Its use in children under 6&nbsp;years of age has not been studied.</p><p>&nbsp;</p><p><u>Chronic rhinosinusitis with nasal polyps</u></p><p>Xolair is not recommended for children and adolescents under 18&nbsp;years of age. Its use in patients under 18&nbsp;years of age has not been studied.</p><p>&nbsp;</p><p><u>Chronic spontaneous urticaria (CSU)</u></p><p>Xolair is not recommended for children under 12&nbsp;years of age. Its use in children under 12 years of age has not been studied.</p><p>&nbsp;</p><p><strong>d. Taking other medicines, herbal or dietary supplements</strong></p><p>Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>This is especially important if you are taking:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat an infection caused by a parasite, as Xolair may reduce the effect of your medicines,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inhaled corticosteroids and other medicines for allergic asthma.</p><p>&nbsp;</p><p><strong>e. Pregnancy and breast-feeding</strong></p><p>If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine. Your doctor will discuss with you the benefits and potential risks of being given this medicine during pregnancy.</p><p>&nbsp;</p><p>If you become pregnant while being treated with Xolair, tell your doctor immediately.</p><p>&nbsp;</p><p>Xolair may pass into breast milk. If you are breast-feeding or plan to breast-feed, ask your doctor for advice before using this medicine.</p><p>&nbsp;</p><p><strong>f. Driving and using machines</strong></p><p>It is unlikely that Xolair will affect your ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Instructions on how to use Xolair are given in the section &ldquo;Information for the healthcare professional&rdquo;.</p><p>&nbsp;</p><p>Xolair is given to you by a doctor or nurse as an injection just under the skin (subcutaneously).</p><p>&nbsp;</p><p>Follow carefully all instructions given by your doctor or nurse.</p><p>&nbsp;</p><p><strong>How much you will be given</strong></p><p><u>Allergic asthma and chronic rhinosinusitis with nasal polyps</u></p><p>Your doctor will decide how much Xolair you need and how often you will be given it. This depends on your body weight and the results of a blood test carried out before the start of the treatment to measure the amount of IgE in your blood.</p><p>&nbsp;</p><p>You will be given 1 to 4&nbsp;injections at a time, either every two weeks, or every four weeks.</p><p>&nbsp;</p><p>Keep taking your current asthma and/or nasal polyps medicine during Xolair treatment. Do not stop taking any asthma and/or nasal polyps medicine without talking to your doctor.</p><p>&nbsp;</p><p>You may not see an immediate improvement after beginning Xolair therapy. In patients with nasal polyps effects have been seen 4&nbsp;weeks after the start of the treatment. In asthma patients it usually takes between 12 and 16&nbsp;weeks to have the full effect.</p><p>&nbsp;</p><p><u>Chronic spontaneous urticaria (CSU)</u></p><p>You will be given two 150&nbsp;mg injections at a time every four weeks.</p><p>&nbsp;</p><p>Keep taking your current medicine for CSU during Xolair treatment. Do not stop taking any medicine without talking to your doctor.</p><p>&nbsp;</p><p><strong>Use in children and adolescents</strong></p><p><u>Allergic asthma</u></p><p>Xolair can be given to children and adolescents aged 6&nbsp;years and older, who are already receiving asthma medicine, but whose asthma symptoms are not well controlled by medicines such as high dose steroid inhalers and beta-agonist inhalers. Your doctor will work out how much Xolair your child needs and how often it needs to be given. This will depend on your child&rsquo;s weight and the results of a blood test carried out before the start of the treatment to measure the amount of IgE in his/her blood.</p><p>&nbsp;</p><p><u>Chronic rhinosinusitis with nasal polyps</u></p><p>Xolair should not be given to children and adolescents under 18&nbsp;years of age.</p><p>&nbsp;</p><p><u>Chronic spontaneous urticaria (CSU)</u></p><p>Xolair can be given to adolescents aged 12&nbsp;years and older, who are already receiving antihistamines but whose CSU symptoms are not well controlled by these medicines. The dose for adolescents aged 12&nbsp;years and above is the same as for adults.</p><p>&nbsp;</p><p><strong>If you forget to take Xolair </strong></p><p>Contact your doctor or hospital as soon as possible to re-schedule your appointment.</p><p>&nbsp;</p><p><strong>If you stop taking Xolair</strong></p><p>Do not stop treatment with Xolair unless your doctor tells you to. Interrupting or stopping the treatment with Xolair may cause your symptoms to come back.</p><p>&nbsp;</p><p>However, if you are being treated for CSU, your doctor may stop Xolair treatment from time to time so that your symptoms can be assessed. Follow your doctor&rsquo;s instructions.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The side effects caused by Xolair are usually mild to moderate but can occasionally be serious.</p><p>&nbsp;</p><p><u>Serious side effects</u>:</p><p>&nbsp;</p><p>Seek medical attention immediately if you notice any signs of the following side effects:</p><p>Rare (may affect up to 1 in 1,000&nbsp;people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe allergic reactions (including anaphylaxis). Symptoms may include rash, itching or hives on the skin, swelling of the face, lips, tongue, larynx (voice box), windpipe or other parts of the body, fast heartbeat, dizziness and light-headedness, confusion, shortness of breath, wheezing or trouble breathing, blue skin or lips, collapsing and losing consciousness. If you have a history of severe allergic reactions (anaphylaxis) unrelated to Xolair you may be more at risk of developing a severe allergic reaction following use of Xolair.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Systemic lupus erythematosus (SLE). Symptoms may include muscle pain, joint pain and swelling, rash, fever, weight loss, and fatigue.</p><p>&nbsp;</p><p>Not known (frequency cannot be estimated from the available data)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Churg-Strauss syndrome or hypereosinophilic syndrome. Symptoms may include one or more of the following: swelling, pain or rash around blood or lymph vessels, high level of a specific type of white blood cells (marked eosinophilia), worsening problems with breathing, nasal congestion, heart problems<strong><em>, </em></strong>pain, numbness, tingling in the arms and legs.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood platelet count with symptoms such as bleeding or bruising more easily than normal.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serum sickness. Symptoms may include one or more of the following: joint pain with or without swelling or stiffness, rash, fever, swollen lymph nodes, muscle pain.</p><p>&nbsp;</p><p><u>Other side effects include:</u></p><p>Very common (may affect more than 1 in 10&nbsp;people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever (in children)</p><p>&nbsp;</p><p>Common (may affect up to 1 in 10&nbsp;people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reactions at the injection site including pain, swelling, itching and redness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in the upper part of the tummy</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache (very common in children)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; upper respiratory tract infection, such as inflammation of the pharynx and common cold</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling of pressure or pain in the cheeks and forehead (sinusitis, sinus headache)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in joints (arthralgia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy</p><p>&nbsp;</p><p>Uncommon (may affect up to 1 in 100&nbsp;people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling, sleepy or tired</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tingling or numbness of the hands or feet</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting, low blood pressure while sitting or standing (postural hypotension), flushing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sore throat, coughing, acute breathing problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea), diarrhoea, indigestion</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching, hives, rash, increased sensitivity of the skin to sun</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight increase</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flu-like symptoms</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling arms</p><p>&nbsp;</p><p>Rare (may affect up to 1 in 1,000&nbsp;people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; parasitic infection</p><p>&nbsp;</p><p>Not known: frequency cannot be estimated from the available data</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain and joint swelling</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the label. The expiry date refers to the last day of that month.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in a refrigerator (2&deg;C - 8&deg;C). Do not freeze.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is omalizumab. One vial contains 150&nbsp;mg of omalizumab. After reconstitution one vial contains 125&nbsp;mg/ml of omalizumab (150&nbsp;mg in 1.2&nbsp;ml).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are sucrose, L-histidine, L-histidine hydrochloride monohydrate and polysorbate&nbsp;20.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Xolair 150 mg powder and solvent for solution for injection is supplied as a white to off-white powder in a small glass vial together with an ampoule containing 2 ml of water for injections. The powder is reconstituted in the water before it is injected by a doctor or nurse.

Xolair 150 mg powder and solvent for solution for injection is available in packs containing 1 vial of powder and 1 ampoule of water for injections.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma AG.&nbsp;<br />www.Novartis.com&nbsp;<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                02/2023

e. To report any side effect(s):
• Saudi Arabia
The National Pharmacovigilance Centre (NPC):
o Fax: +966-11-205-7662
o SFDA call center: 19999
o E-mail: npc.drug@sfda.gov.sa
o Website: https://ade.sfda.gov.sa
Patient Safety Department Novartis Consulting AG - Saudi Arabia:
o Toll Free Number: 8001240078
o Phone: +966112658100
o Fax: +966112658107
o Email: adverse.events@novartis.com
• Other GCC States:
- Please contact the relevant competent authority.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي عقار زولير على المادة الفعَّالة أوماليزوماب. أوماليزوماب عبارة عن بروتين من صنع البشر وهو مماثل للبروتينات الطبيعية التي ينتجها الجسم. فهو ينتمي إلى فئة من الأدوية تُسمى الأجسام المضادة أحادية النسيلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم عقار زولير لعلاج الحالات الآتية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الربو التحسسي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأنف والجيوب الأنفية المزمن المصحوب بسَلائِل أَنْفِيَّة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأرتكاريا التلقائية المزمنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الربو التَّحسسي</u></p><p dir="RTL">يُستخدم هذا الدَّواء لمنع تفاقم مرض الربو عن طريق التَّحكم في أعراض الربو التَّحسسي الشَّديد لدى البالغين والمراهقين والأطفال (بعمر 6 أعوام فأكبر) ممن يتلقون بالفعل دواء للربو، لكن أعراض الربو لديهم لا يتم التَّحكم فيها بشكل جيد عن طريق استخدام أدوية مثل أجهزة الاستنشاق التي تحتوي على الستيرويدات وناهضات بيتا بجرعة مرتفعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>التهاب الأنف والجيوب الأنفية المزمن المصحوب بسَلائِل أَنْفِيَّة</u></p><p dir="RTL">يُستخدم هذا الدَّواء لعلاج التهاب الأنف والجيوب الأنفية المزمن المصحوب بسَلائِل أَنْفِيَّة لدى البالغين (بعمر 18 عامًا فأكبر) ممن يتلقون بالفعل الكورتيكوستيرويدات داخل الأنف (بخاخ للأنف يحتوي على كورتيكوستيرويد) ولكن لا يتم التَّحكم في الأعراض لديهم بشكل جيد عن طريق استخدام هذه الأدوية. السَّلائِلُ الأَنْفِيَّة هي عبارة عن زوائد صغيرة ببطانة الأنف. يساعد عقار زولير على خفض حجم السلائل كما يحسن الأعراض، بما في ذلك احتقان الأنف وفقدان حاسة الشم ووجود مخاط بالجزء الخلفي من الحلق وسيلان الأنف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأرتكاريا التلقائية المزمنة</u></p><p dir="RTL">يُستخدم هذا الدَّواء لعلاج الأرتكاريا التلقائية المزمنة لدى البالغين والمراهقين (بعمر 12 عامًا فأكبر) ممن يتلقون بالفعل مضادات الهيستامين ولكن أعراض الأرتكاريا التلقائية المزمنة التي يعانون منها لا يتم التَّحكم فيها بشكل جيد عن طريق استخدام هذه الأدوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يعمل عقار زولير عن طريق إعاقة مادة تُسمى الجلوبيولين المناعي &quot;E&quot;، والتي ينتجها الجسم. يساهم الجلوبيولين المناعي &quot;E&quot; في حدوث نوع من الالتهاب الذي يلعب دورًا رئيسيًّا في التَّسبب بالإصابة بالربو التحسسي، والتهاب الأنف والجيوب المزمن المصحوب بسَلائِل أَنْفِيَّة والأرتكاريا التلقائية المزمنة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&zwnj;أ.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>موانع استعمال عقار زولير:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه أوماليزوماب أو تجاه أي مكون من المكونات الأخرى الموجودة بهذا الدَّواء (المدرجة في القسم: 6).</p><p dir="RTL">إذا كنت تعتقد أنك قد تكون لديك حساسية تجاه أيٍّ من المكونات، فأخبر طبيبك؛ حينها يجب ألا يتم إعطاؤك عقار زولير.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;ب.&nbsp;&nbsp;&nbsp; </strong><strong>الاحتياطات عند استعمال عقار زولير</strong></p><p dir="RTL">تحدَّث إلى طبيبك قبل استخدام عقار زولير في الحالات الآتية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل بالكلى أو الكبد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من اضطرابٍ يهاجم فيه جهازك المناعي أجزاء من جسمك (مرض مناعي ذاتي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مسافرًا إلى منطقة تنتشر فيها العدوى الناجمة عن الطفيليات - فقد يُضعِف عقار زولير مقاومتك تجاه هذه العدوى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كُنت قد أصبت سابقًا بتفاعل حساسية شديد (الحساسية المفرطة)، على سبيل المثال ناجم عن استخدام أحد الأدوية، أو لدغة حشرة أو تناول الطعام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يُعالج عقار زولير أعراض مرض الربو الحاد، مثل نوبة الربو المفاجئة. لذلك، يجب عدم استخدام عقار زولير لعلاج هذه الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ليس المقصود من استخدام عقار زولير الوقاية من الحالات الأخرى من النوع التحسسي أو علاجها، مثل تفاعلات الحساسية المفاجئة، متلازمة فرط الجلوبيولين المناعي &quot;E&quot; (وهو اضطراب مناعي وراثي)، داء الرَّشَّاشِيَّات (وهو مرض رئوي مرتبط بالفطريات)، حساسية الطعام، الأكزيما أو حُمَّى القش؛ نظرًا لعدم دراسة استخدام عقار زولير في هذه الحالات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>البحث عن علامات تفاعلات الحساسية وغيرها من الأعراض الجانبية الخطيرة</strong></p><p dir="RTL">من الممكن أن يسبب عقار زولير أعراضًا جانبية خطيرة. يجب عليك البحث عن علامات هذه الحالات أثناء استخدام عقار زولير. اطلب المساعدة الطبية فورًا إذا لاحظت أية علامات تدل على احتمالية وجود أعراض جانبية خطيرة. هذه العلامات مُدرجة تحت &quot;الأعراض الجانبية الخطيرة&quot; في القسم 4. تحدث أغلب تفاعلات الحساسية الشديدة خلال تلقي أول 3 جرعات من عقار زولير.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;ج.&nbsp;&nbsp;&nbsp; </strong><strong>الأطفال والمراهقون</strong></p><p dir="RTL"><u>الربو التَّحسسي</u></p><p dir="RTL">لا يوصى باستخدام عقار زولير للأطفال ممن تقل أعمارهم عن 6 أعوام. لم تتم دراسة استخدام العقار في الأطفال ممن تقل أعمارهم عن 6 أعوام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>التهاب الأنف والجيوب الأنفية المزمن المصحوب بسَلائِل أَنْفِيَّة</u></p><p dir="RTL">لا يوصى باستخدام عقار زولير للأطفال والمراهقين ممن تقل أعمارهم عن 18 عامًا. لم تتم دراسة استخدام العقار في المرضى الذين تقل أعمارهم عن 18 عامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأرتكاريا التلقائية المزمنة</u></p><p dir="RTL">لا يوصى باستخدام عقار زولير للأطفال ممن تقل أعمارهم عن 12 عامًا. لم تتم دراسة استخدام العقار في الأطفال ممن تقل أعمارهم عن 12 عامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;د.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>التداخلات الدوائية من اخذ هذا المستحضر مع أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">يُرجى إخبار طبيبك أو الصيدلي أو الممرض الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">هذا مهم بشكل خاص إذا كنت تتناول الآتي:</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الأدوية التي تستخدم لعلاج العدوى الناجمة عن أحد الطفيليات؛ حيث إن عقار زولير قد يخفض من تأثير الأدوية الخاصة بك،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكورتيكوستيرويدات المستنشقة وغيرها من أدوية علاج الربو التحسسي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>هـ.&nbsp;&nbsp; &nbsp;الحمل والرضاعة</strong></p><p dir="RTL">إذا كنتِ حاملًا، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين للحمل، فاستشيري طبيبك قبل استخدام هذا الدَّواء. فسيناقش معكِ طبيبكِ الفوائد والمخاطر المُحتملة لإعطاء هذا الدَّواء أثناء فترة الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبحتِ حاملًا أثناء العلاج بعقار زولير، فيجب عليكِ إخبار طبيبكِ فورًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يمر عقار زولير في حليب الأم. إذا كنتِ مرضعًا أو تخططين لممارسة الرضاعة الطبيعية، فاستشيري طبيبكِ قبل استخدام هذا الدَّواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>و.&nbsp;&nbsp;&nbsp; تأثير عقار زولير على القيادة واستخدام الآلات</strong></p><p dir="RTL">من غير المرجح أن يُؤثر عقار زولير في قدرتك على القيادة واستخدام الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تتوافر تعليمات حول كيفية إعطاء عقار زولير في قسم: &quot;معلومات لأخصائي الرعاية الصحية&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم إعطاؤك عقار زولير من قبل طبيب أو ممرض &nbsp;على شكل حقن تحت الجلد مباشرةً.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اتبع بعناية كافة التعليمات التي أعطاها لك طبيبك أو الممرض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما هي الكمية التي سيتم إعطاؤها لك؟</strong></p><p dir="RTL"><u>الربو التحسسي والتهاب الأنف والجيوب الأنفية المزمن المصحوب بسَلائِل أَنْفِيَّة</u></p><p dir="RTL">سيقرر طبيبك كمية عقار زولير التي تحتاجها وعدد المرات التي ستحتاجها. يعتمد ذلك على وزن جسمك ونتائج اختبار الدَّم الذي تم إجراؤه قبل بدء العلاج لقياس كمية الجلوبيولين المناعي &quot;E&quot; لديك بالدَّم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيتم إعطاؤك ما يتراوح بين حقنة واحدة و4 حقن مرة واحدة، إما كل أسبوعين أو كل أربعة أسابيع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استمر في تناول دواء الربو الحالي و/أو السَلائِل الأَنْفِيَّة الخاص بك أثناء العلاج بعقار زولير. يجب ألا تتوقف عن تناوُل أية أدوية للربو و/أو السَلاَئِل الأَنْفِيَّة دون التَّحدث إلى طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا تلاحظ تحسنًا فوريًّا بعد بدء العلاج بعقار زولير. لُوحظ لدى المرضى الذين يعانون من سَلائِل أَنْفِيَّة آثار بعد 4 أسابيع من بدء العلاج. عادة ما يستغرق ذلك ما بين 12 و16 أسبوعًا في المرضى الذين يعانون من الربو؛ للحصول على التَّأثير الكامل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأرتكاريا التلقائية المزمنة</u></p><p dir="RTL">ستكون بحاجة إلى تلقي حقنتين بمقدار 150 مجم في المرة الواحدة كل أربعة أسابيع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استمر في تناول دواء الأرتكاريا التلقائيَّة المزمنة الحالي الخاص بك أثناء العلاج بعقار زولير. يجب ألا تتوقف عن تلقي أي دواء دون التَّحدث إلى طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام في الأطفال والمراهقين</strong></p><p dir="RTL"><u>الربو التَّحسسي</u></p><p dir="RTL">من الممكن استخدام عقار زولير في الأطفال والمراهقين بعمر 6 أعوام فأكبر، ممن يتلقون بالفعل دواء للربو، لكن أعراض الربو لديهم لا يتم التحكم فيها بشكل جيد عن طريق استخدام أدوية مثل أجهزة الاستنشاق التي تحتوي على الستيرويدات أو ناهضات بيتا بجرعة مرتفعة. سيحدد طبيبك كمية عقار زولير التي يحتاجها طفلك/طفلتك وعدد المرات اللازمة لإعطائها. سيعتمد ذلك على وزن طفلك/ طفلتك ونتائج اختبار الدَّم الذي تم إجراؤه قبل بدء العلاج لقياس كمية الجلوبيولين المناعي &quot;E&quot; في دمه/ دمها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>التهاب الأنف والجيوب الأنفية المزمن المصحوب بسَلائِل أَنْفِيَّة</u></p><p dir="RTL">لا يجب إعطاء عقار زولير للأطفال والمراهقين الأقل من 18 سنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأرتكاريا التلقائية المزمنة</u></p><p dir="RTL">من الممكن استخدام عقار زولير في المراهقين بعمر 12 عامًا فأكبر، ممن يتلقون بالفعل مضادات الهيستامين ولكن أعراض الأرتكاريا التلقائيَّة المزمنة التي يعانون منها لا يتم التحكم فيها بشكل جيد عن طريق استخدام هذه الأدوية. تكون الجرعة بالنسبة للمراهقين بعمر 12 عامًا فأكبر هي نفسها التي تُستخدم بالنسبة للبالغين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نسيان تناول جرعة من عقار زولير </strong></p><p dir="RTL">اتصل بطبيبك أو المستشفى في أقرب وقت ممكن لإعادة تحديد موعد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التوقف عن تناول عقار زولير</strong></p><p dir="RTL">لا توقف العلاج بعقار زولير ما لم يخبرك طبيبك بذلك. قد يسبب قطع أو إيقاف العلاج بعقار زولير معاودة الأعراض لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">مع ذلك، إذا كنت تُعالج من الأرتكاريا التلقائية المزمنة، فقد يوقف طبيبك العلاج باستخدام عقار زولير من وقت لآخر حتى يمكن تقييم الأعراض التي تعاني منها. يُرجى اتباع تعليمات طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشيري طبيبك أو الصيدلي أو الممرض الخاص بك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء أعراضًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع. عادةً ما تكون الأعراض<strong> </strong>الجانبية النَّاجمة عن استخدام عقار زولير خفيفة إلى متوسطة، ولكنها قد تكون خطيرة أحيانًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأعراض الجانبية الخطيرة:</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">اطلب العناية الطبية فورًا إذا لاحظت أي علامات للأعراض الجانبية الآتية:</p><p dir="RTL">نادرة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 1000 شخص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية شديدة (بما في ذلك الحساسية المفرطة). قد تشمل الأعراض طفحًا جلديًّا أو حكة أو شرى (أرتكاريا) على الجلد، تورمًا بالوجه، الشفتين، اللسان، الحنجرة، الرُّغامَى (القصبة الهوائية) أو أجزاء أخرى من الجسم، تسارع ضربات القلب، دوخة وشعورًا بخفة الرَّأس، ارتباكًا، ضيق التنفس، أزيزًا بالصدر أو صعوبة في التنفس، تحول لون الجلد أو الشفتين إلى اللون الأزرق، هبوطًا وفقدان الوعي. إذا كان لديك تاريخ مرضي من الإصابة بتفاعلات الحساسية الشديدة (الحساسية المفرطة) غير المرتبطة بعقار زولير، فقد تكون أكثر عرضة لخطر الإصابة بأحد تفاعلات الحساسية الشديدة بعد استخدام عقار زولير.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الذئبة الحمامية الجهازِية. قد تتضمن الأعراض ألمًا في العضلات وألمًا وتورمًا بالمفاصل وطفحًا جلديًّا وحمى وفقدان الوزن وإرهاقًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">غير معروفة (لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة)</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>متلازمة شيرج -ستراوس أو متلازمة فرط اليوزينيات. قد تتضمن الأعراض واحدًا أو أكثر مما يلي: تورمًا، ألمًا أو طفحًا جلديًّا حول الأوعية الدَّموية أو الليمفاوية، ارتفاع مستوى نوع معين من خلايا الدَّم البيضاء (كثرة ملحوظة بعدد خلايا اليُوزينِيَّات)، تفاقم مشاكل التَّنفس، احتقان الأنف، مشاكل القلب، ألمًا، تنميلًا، وخزًا بالذراعين والساقين.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>انخفاض تعداد الصفائح الدَّموية مع أعراض مثل النزيف أو التَّكدم بسهولة بشكل أكثر من المعتاد.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>داء المصل. قد تشمل الأعراض واحدًا أو أكثر مما يلي: ألمًا بالمفاصل مع أو بدون تورم أو تيبُّس، طفحًا جلديًّا، حمى، تورم العقد الليمفاوية، ألمًا في العضلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>تتضمن الأعراض الجانبية الأخرى ما يلي:</u></p><p dir="RTL">شائعة جدًّا (قد تُؤثر على أكثر من شخص واحد من بين كل 10&nbsp;أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى (في الأطفال).</p><p dir="RTL">&nbsp;</p><p dir="RTL">شائعة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10&nbsp;أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات بموضع الحقن، بما في ذلك ألم وتورم وحكة واحمرار.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالجزء العلوي من البطن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع (شائع جدًّا في الأطفال).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى بالجهاز التَّنفسي العلوي، مثل التهاب البلعوم والإصابة بنزلة برد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بضغط أو ألم في الخدين والجبهة (الْتِهاب الجُيوب الأنفية وصداع الجيوب الأنفية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالمفاصل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالدوخة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">غير شائعة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بنعاس أو تعب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وخز أو تنميل باليدين أو القدمين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إغماء، انخفاض ضغط الدَّم أثناء الجلوس أو الوقوف (انخفاض ضغط الدم الوضعي)، احمرار الجلد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الحلق، سعال، مشاكل حادة بالتَّنفس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإعياء (الغثيان)، إسهال وعسر الهضم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة، شرى (أرتكاريا)، طفح جلدي، زيادة حساسية الجلد تجاه الشمس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض شبيهة بأعراض الإنفلونزا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورُّم بالذراعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">نادرة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 1000 شخص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى طفيلية</p><p dir="RTL">&nbsp;</p><p dir="RTL">غير معروفة: لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالعضلات وتورم المفاصل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدَّواء بعد تاريخ انتهاء الصَّلاحية المدون على الملصق. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في الثلاجة (عند 2&mdash;8 درجات مئوية). لا تعرضه للتَّجميد.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي أوماليزوماب. تحتوي الزجاجة الواحدة على 150 مجم أوماليزوماب. بعد الإعداد، تحتوي الزجاجة الواحدة على 125 مجم/ مللي لتر أوماليزوماب (150 مجم في 1.2 مللي لتر).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي السكروز، إل-هستيدين، إل-هستيدين هيدروكلوريد أحادي الهيدرات وبوليسوربات 20.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتوفر عقار زولير 150 مجم مسحوق ومُذيب لإعداد محلول للحقن على هيئة مسحوق أبيض مائل للصفرة في زجاجة صغيرة مزودة بأمبولة بها 2 مللي لتر من ماء للحقن. يتم تحضير المسحوق في الماء قبل حقنه من قبل طبيب أو ممرض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوار عقار زولير 150 مجم مسحوق ومُذيب لإعداد محلول للحقن في عبوات تحتوي على زجاجة واحدة من المسحوق وأمبولة واحدة بها ماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك حق التَّسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.<br />www.Novartis.com&nbsp;<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            02/2023
هـ. للإبلاغ عن الأعراض الجانبية:
•	المملكة العربية السعودية

المركز الوطني للتَّيقظ والسَّلامة الدَّوائية (NPC):

o	الفاكس: +966-11-205-7662
o	مركز اتصال الهيئة السعودية للغذاء والدَّواء: 19999
o	البريد الإلكتروني: npc.drug@sfda.gov.sa
o	الموقع الإلكتروني: https://ade.sfda.gov.sa 

شركة نوفارتس - المملكة العربية السعودية - قسم سلامة المرضى:
o	الهاتف المجاني: 8001240078
o	الهاتف: 966112658100 +
o	الفاكس: 966112658107+
o	البريد الإلكتروني: adverse.events@novartis.com  

•	دول مجلس التَّعاون الخليجي الأخرى:
	يُرجى الاتصال بسلطات الاختصاص المعنية.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Xolair 150 mg powder and solvent for solution for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One vial contains 150 mg of omalizumab*.

*Omalizumab is a humanised monoclonal antibody manufactured by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell line.

After reconstitution one vial contains 125 mg/ml of omalizumab (150 mg in 1.2 ml).

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and solvent for solution for injection.

Xolair is an off-white lyophilised powder.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.1 Therapeutic indications:</p><p>Allergic asthma</p><p>Xolair is indicated in adults, adolescents and children (6 to &lt;12&nbsp;years of age).</p><p>&nbsp;</p><p>Xolair treatment should only be considered for patients with convincing IgE (immunoglobulin E) mediated asthma (see section 4.2).</p><p>&nbsp;</p><p><em><u>Adults and adolescents (12&nbsp;years of age and older)</u></em></p><p>Xolair is indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function (FEV1 &lt;80%) as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.</p><p>&nbsp;</p><p><em><u>Children (6 to &lt;12&nbsp;years of age)</u></em></p><p>Xolair is indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.</p><p><u>Chronic rhinosinusitis with nasal polyps (CRSwNP)</u></p><p>Xolair is indicated as an add-on therapy with intranasal corticosteroids (INC) for the treatment of adults (18&nbsp;years and above) with severe CRSwNP for whom therapy with INC does not provide adequate disease control.</p><p>&nbsp;</p><p><u>Chronic spontaneous urticaria (CSU)</u></p><p>Xolair is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12&nbsp;years and above) patients with inadequate response to H1 antihistamine treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Xolair treatment should be initiated by physicians experienced in the diagnosis and treatment of severe persistent asthma,&nbsp;chronic rhinosinusitis with nasal polyps (CRSwNP) or chronic spontaneous urticaria.</p><p>&nbsp;</p><p><em><u>Posology</u></em></p><p><em><u>Allergic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP)</u></em></p><p>Dosing for allergic asthma and CRSwNP follows the same dosing principles. The appropriate dose and frequency of Xolair for these conditions is determined by baseline IgE (IU/ml), measured before the start of treatment, and body weight (kg). Prior to administration of the initial dose, patients should have their IgE level determined by any commercial serum total IgE assay for their dose assignment. Based on these measurements, 75 to 600&nbsp;mg of Xolair in 1 to 4&nbsp;injections may be needed for each administration.</p><p>&nbsp;</p><p>Allergic asthma Patients with IgE lower than 76&nbsp;IU/ml were less likely to experience benefit (see section 5.1). Prescribing physicians should ensure that adult and adolescent patients with IgE below 76&nbsp;IU/ml and children (6 to &lt;&nbsp;12&nbsp;years of age) with IgE below 200&nbsp;IU/ml have unequivocal <em>in vitro</em> reactivity (RAST) to a perennial allergen before starting therapy.</p><p>&nbsp;</p><p>See Table&nbsp;1 for a conversion chart and Tables&nbsp;2 and 3 for the dose determination charts.&nbsp;</p><p>&nbsp;</p><p>Patients whose baseline IgE levels or body weight in kilograms are outside the limits of the dose table should not be given Xolair.</p><p>&nbsp;</p><p>The maximum recommended dose is 600&nbsp;mg omalizumab every two weeks.</p><p>&nbsp;</p><p><strong>Table&nbsp;1: Conversion from dose to number of vials, number of injections and total injection volume for each administration</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Dose (mg)</p></td><td colspan="2" style="vertical-align:top"><p>Number of vials</p></td><td style="vertical-align:top"><p>Number of injections</p></td><td style="vertical-align:top"><p>Total injection volume (ml)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>75&nbsp;mg<sup> a</sup></p></td><td style="vertical-align:top"><p>150&nbsp;mg<sup> b</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>75</p></td><td style="vertical-align:top"><p>1<sup>c</sup></p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0.6</p></td></tr><tr><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1.2</p></td></tr><tr><td style="vertical-align:top"><p>225</p></td><td style="vertical-align:top"><p>1<sup>c</sup></p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>1.8</p></td></tr><tr><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2.4</p></td></tr><tr><td style="vertical-align:top"><p>375</p></td><td style="vertical-align:top"><p>1<sup>c</sup></p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>3.0</p></td></tr><tr><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>3.6</p></td></tr><tr><td style="vertical-align:top"><p>525</p></td><td style="vertical-align:top"><p>1<sup>c</sup></p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>4.2</p></td></tr><tr><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>4.8</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>a </sup>0.6&nbsp;ml = maximum delivered volume per vial (Xolair 75&nbsp;mg).</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>b </sup>1.2&nbsp;ml = maximum delivered volume per vial (Xolair 150&nbsp;mg).</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>c </sup>or use 0.6&nbsp;ml from a 150&nbsp;mg vial.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Table&nbsp;2: ADMINISTRATION EVERY 4&nbsp;WEEKS. Xolair doses (milligrams per dose) administered by subcutaneous injection every 4&nbsp;weeks</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td colspan="10" style="vertical-align:bottom"><p><strong>Body weight (kg)</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Baseline IgE (IU/ml)</strong></p></td><td style="vertical-align:bottom"><p>&sup3;20‑25</p></td><td style="vertical-align:bottom"><p>&gt;25‑30</p></td><td style="vertical-align:bottom"><p>&gt;30‑40</p></td><td style="vertical-align:bottom"><p>&gt;40‑50</p></td><td style="vertical-align:bottom"><p>&gt;50‑60</p></td><td style="vertical-align:bottom"><p>&gt;60‑70</p></td><td style="vertical-align:bottom"><p>&gt;70‑80</p></td><td style="vertical-align:bottom"><p>&gt;80‑90</p></td><td style="vertical-align:bottom"><p>&gt;90-125</p></td><td style="vertical-align:bottom"><p>&gt;125-150</p></td></tr><tr><td style="vertical-align:top"><p>&sup3;30‑100</p></td><td style="vertical-align:top"><p>75</p></td><td style="vertical-align:top"><p>75</p></td><td style="vertical-align:top"><p>75</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>300</p></td></tr><tr><td style="vertical-align:top"><p>&gt;100‑200</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>600</p></td></tr><tr><td style="vertical-align:top"><p>&gt;200‑300</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>225</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;300‑400</p></td><td style="vertical-align:top"><p>225</p></td><td style="vertical-align:top"><p>225</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;400‑500</p></td><td style="vertical-align:top"><p>225</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;500‑600</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;600‑700</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;700-800</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;800-900</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="5" rowspan="2" style="vertical-align:top"><p>ADMINISTRATION EVERY 2&nbsp;WEEKS</p><p>SEE TABLE&nbsp;3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;900-1000</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;1000-1100</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Table&nbsp;3: ADMINSTRATION EVERY 2&nbsp;WEEKS. Xolair doses (milligrams per dose) administered by subcutaneous injection every 2&nbsp;weeks</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:614px"><tbody><tr><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td colspan="12" style="vertical-align:bottom"><p><strong>Body weight (kg)</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Baseline IgE (IU/ml)</strong></p></td><td style="vertical-align:bottom"><p>&sup3;20‑ 25*</p></td><td style="vertical-align:bottom"><p>&gt;25‑ 30*</p></td><td style="vertical-align:bottom"><p>&gt;30‑<br />40</p></td><td style="vertical-align:bottom"><p>&gt;40‑<br />50</p></td><td style="vertical-align:bottom"><p>&gt;50‑<br />60</p></td><td style="vertical-align:bottom"><p>&gt;60‑<br />70</p></td><td style="vertical-align:bottom"><p>&gt;70‑<br />80</p></td><td style="vertical-align:bottom"><p>&gt;80‑<br />90</p></td><td colspan="2" style="vertical-align:bottom"><p>&gt;90‑<br />125</p></td><td colspan="2" style="vertical-align:bottom"><p>&gt;125‑150</p></td></tr><tr><td style="vertical-align:top"><p>&sup3;30‑100</p></td><td colspan="5" rowspan="2" style="vertical-align:top"><p>ADMINISTRATION EVERY 4&nbsp;WEEKS</p><p>SEE TABLE&nbsp;2</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;100‑200</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;200‑300</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>375</p></td></tr><tr><td style="vertical-align:top"><p>&gt;300‑400</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>450</p></td><td colspan="2" style="vertical-align:top"><p>525</p></td></tr><tr><td style="vertical-align:top"><p>&gt;400‑500</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>375</p></td><td style="vertical-align:top"><p>375</p></td><td colspan="2" style="vertical-align:top"><p>525</p></td><td colspan="2" style="vertical-align:top"><p>600</p></td></tr><tr><td style="vertical-align:top"><p>&gt;500‑600</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>375</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>450</p></td><td colspan="2" style="vertical-align:top"><p>600</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;600‑700</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>225</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>375</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>525</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;700‑800</p></td><td style="vertical-align:top"><p>225</p></td><td style="vertical-align:top"><p>225</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>375</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>525</p></td><td style="vertical-align:top"><p>600</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;800‑900</p></td><td style="vertical-align:top"><p>225</p></td><td style="vertical-align:top"><p>225</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>375</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>525</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;900-1000</p></td><td style="vertical-align:top"><p>225</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>375</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>525</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;1000-1100</p></td><td style="vertical-align:top"><p>225</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>375</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;1100-1200</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>525</p></td><td style="vertical-align:top"><p>600</p></td><td colspan="7" style="vertical-align:top"><p>Insufficient data to recommend a dose</p></td></tr><tr><td style="vertical-align:top"><p>&gt;1200-1300</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>375</p></td><td style="vertical-align:top"><p>450</p></td><td style="vertical-align:top"><p>525</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;1300-1500</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>375</p></td><td style="vertical-align:top"><p>525</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody></tbody></table><p>*Body weights below 30&nbsp;kg were not studied in the pivotal trials for CRSwNP.</p><p>&nbsp;</p><p><em>Treatment duration, monitoring and dose adjustments</em></p><p><em>Allergic asthma</em></p><p>Xolair is intended for long-term treatment.<strong><em> </em></strong>Clinical trials have demonstrated that it takes at least 12‑16&nbsp;weeks for Xolair treatment to show effectiveness. At 16&nbsp;weeks after commencing Xolair therapy patients should be assessed by their physician for treatment effectiveness before further injections are administered. The decision to continue Xolair following the 16-week timepoint, or on subsequent occasions, should be based on whether a marked improvement in overall asthma control is seen (see section 5.1, Physician&rsquo;s overall assessment of treatment effectiveness).</p><p>&nbsp;</p><p><em>Chronic rhinosinusitis with nasal polyps (CRSwNP)</em></p><p>In clinical trials for CRSwNP, changes in nasal polyps score (NPS) and nasal congestion score (NCS) were observed at 4&nbsp;weeks. The need for continued therapy should be periodically reassessed based upon the patient&rsquo;s disease severity and level of symptom control.</p><p>&nbsp;</p><p><em>Allergic asthma and </em><em>chronic rhinosinusitis with nasal polyps (CRSwNP)</em></p><p>Discontinuation of Xolair treatment generally results in a return to elevated free IgE levels and associated symptoms. Total IgE levels are elevated during treatment and remain elevated for up to one year after the discontinuation of treatment. Therefore, re-testing of IgE levels during Xolair treatment cannot be used as a guide for dose determination. Dose determination after treatment interruptions lasting less than one year should be based on serum IgE levels obtained at the initial dose determination. Total serum IgE levels may be re-tested for dose determination if treatment with Xolair has been interrupted for one year or more.</p><p>&nbsp;</p><p>Doses should be adjusted for significant changes in body weight (see Tables&nbsp;2 and 3).</p><p>&nbsp;</p><p><u>Chronic spontaneous urticaria (CSU)</u></p><p><em><u>Posology</u></em></p><p>The recommended dose is 300&nbsp;mg by subcutaneous injection every four weeks.</p><p>&nbsp;</p><p>Prescribers are advised to periodically reassess the need for continued therapy.</p><p>&nbsp;</p><p>Clinical trial experience of long-term treatment in this indication is described in section 5.1.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em><u>Elderly (65&nbsp;years of age and older)</u></em></p><p>There are limited data available on the use of Xolair in patients older than 65&nbsp;years but there is no evidence that elderly patients require a different dose from younger adult patients.</p><p>&nbsp;</p><p><em><u>Renal or hepatic impairment</u></em></p><p>There have been no studies on the effect of impaired renal or hepatic function on the pharmacokinetics of omalizumab. Because omalizumab clearance at clinical doses is dominated by the reticular endothelial system (RES) it is unlikely to be altered by renal or hepatic impairment. While no particular dose adjustment is recommended for these patients, Xolair should be administered with caution (see section 4.4).</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>In allergic asthma, the safety and efficacy of Xolair in paediatric patients below the age of 6&nbsp;years have not been established. No data are available.</p><p>&nbsp;</p><p>In CRSwNP, the safety and efficacy of Xolair in patients below the age of 18&nbsp;years have not been established.</p><p>&nbsp;</p><p>In CSU, the safety and efficacy of Xolair in paediatric patients below the age of 12&nbsp;years have not been established.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>For subcutaneous administration only.&nbsp;Xolair must not be administered by the intravenous or intramuscular route.</p><p>&nbsp;</p><p>Doses of more than 150&nbsp;mg (Table&nbsp;1) should be divided across two or more injection sites.</p><p>&nbsp;</p><p>There is limited experience with self-administration of Xolair powder and solvent for solution for injection. Therefore, treatment with this formulation is intended to be administered by a healthcare provider only.</p><p>&nbsp;</p><p>For instructions on reconstitution of the medicinal product before administration, see section 6.6 and also information for the healthcare professional section of the package leaflet.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>&nbsp;</p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p><u>General</u></p><p>Xolair is not indicated for the treatment of acute asthma exacerbations, acute bronchospasm or status asthmaticus.</p><p>&nbsp;</p><p>Xolair has not been studied in patients with hyperimmunoglobulin E syndrome or allergic bronchopulmonary aspergillosis or for the prevention of anaphylactic reactions, including those provoked by food allergy, atopic dermatitis, or allergic rhinitis. Xolair is not indicated for the treatment of these conditions.</p><p>&nbsp;</p><p>Xolair therapy has not been studied in patients with autoimmune diseases, immune complex-mediated conditions, or pre-existing renal or hepatic impairment (see section 4.2). Caution should be exercised when administering Xolair in these patient populations.</p><p>&nbsp;</p><p>Abrupt discontinuation of systemic or inhaled corticosteroids after initiation of Xolair therapy is not recommended. Decreases in corticosteroids should be performed under the direct supervision of a physician and may need to be performed gradually.</p><p>&nbsp;</p><p><u>Immune system disorders</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions type&nbsp;I</p><p>Type&nbsp;I local or systemic allergic reactions, including anaphylaxis and anaphylactic shock, may occur when taking omalizumab, even after a long duration of treatment. However, Most of these reactions occurred within 2&nbsp;hours after the first and subsequent injections of Xolair but some started beyond 2&nbsp;hours and even beyond 24&nbsp;hours after the injection. The majority of anaphylactic reactions occurred within the first 3&nbsp;doses of Xolair. A history of anaphylaxis unrelated to omalizumab may be a risk factor for anaphylaxis following Xolair administration. Therefore medicinal products for the treatment of anaphylactic reactions should always be available for immediate use following administration of Xolair. If an anaphylactic or other serious allergic reaction occurs, administration of Xolair must be discontinued immediately, and appropriate therapy initiated. Patients should be informed that such reactions are possible and prompt medical attention should be sought if allergic reactions occur.</p><p>&nbsp;</p><p>Antibodies to omalizumab have been detected in a low number of patients in clinical trials (see section 4.8). The clinical relevance of anti-Xolair antibodies is not well understood.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serum sickness</p><p>Serum sickness and serum sickness-like reactions, which are delayed allergic type&nbsp;III reactions, have been seen in patients treated with humanised monoclonal antibodies including omalizumab. The suggested pathophysiologic mechanism includes immune-complex formation and deposition due to development of antibodies against omalizumab. The onset has typically been 1‑5&nbsp;days after administration of the first or subsequent injections, also after long duration of treatment. Symptoms suggestive of serum sickness include arthritis/arthralgias, rash (urticaria or other forms), fever and lymphadenopathy. Antihistamines and corticosteroids may be useful for preventing or treating this disorder, and patients should be advised to report any suspected symptoms.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Churg-Strauss syndrome and hypereosinophilic syndrome</p><p>Patients with severe asthma may rarely present systemic hypereosinophilic syndrome or allergic eosinophilic granulomatous vasculitis (Churg-Strauss syndrome), both of which are usually treated with systemic corticosteroids.</p><p>&nbsp;</p><p>In rare cases, patients on therapy with anti-asthma medicinal products, including omalizumab, may present or develop systemic eosinophilia and vasculitis. These events are commonly associated with the reduction of oral corticosteroid therapy.</p><p>&nbsp;</p><p>In these patients, physicians should be alert to the development of marked eosinophilia, vasculitic rash, worsening pulmonary symptoms, paranasal sinus abnormalities, cardiac complications, and/or neuropathy.</p><p><u>&nbsp;</u></p><p>Discontinuation of omalizumab should be considered in all severe cases with the above mentioned immune system disorders.</p><p><u>&nbsp;</u></p><p><u>Parasitic (helminth) infections</u></p><p>IgE may be involved in the immunological response to some helminth infections. In patients at chronic high risk of helminth infection, a placebo-controlled trial in allergic patients showed a slight increase in infection rate with omalizumab, although the course, severity, and response to treatment of infection were unaltered. The helminth infection rate in the overall clinical programme, which was not designed to detect such infections, was less than 1 in 1,000&nbsp;patients. However, caution may be warranted in patients at high risk of helminth infection, in particular when travelling to areas where helminthic infections are endemic. If patients do not respond to recommended anti-helminth treatment, discontinuation of Xolair should be considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Since IgE may be involved in the immunological response to some helmith infections, Xolair may indirectly reduce the efficacy of medicinal products for the treatment of helminthic or other parasitic infections (see section&nbsp;4.4).</p><p>&nbsp;</p><p>Cytochrome P450 enzymes, efflux pumps and protein-binding mechanisms are not involved in the clearance of omalizumab; thus, there is little potential for drug-drug interactions. Medicinal product or vaccine interaction studies have not been performed with Xolair. There is no pharmacological reason to expect that commonly prescribed medicinal products used in the treatment of asthma or CSU will interact with omalizumab.</p><p>&nbsp;</p><p><u>Allergic asthma</u></p><p>In clinical studies Xolair was commonly used in conjunction with inhaled and oral corticosteroids, inhaled short-acting and long-acting beta agonists, leukotriene modifiers, theophyllines and oral antihistamines. There was no indication that the safety of Xolair was altered with these other commonly used anti-asthma medicinal products. Limited data are available on the use of Xolair in combination with specific immunotherapy (hypo-sensitisation therapy). In a clinical trial where Xolair was co-administered with immunotherapy, the safety and efficacy of Xolair in combination with specific immunotherapy were found to be no different to that of Xolair alone.</p><p>&nbsp;</p><p><u>Chronic rhinosinusitis with nasal polyps (CRSwNP)</u></p><p>In clinical studies Xolair was used in conjunction with intranasal mometasone spray as per protocol. Other commonly used concomitant medicinal products included other intranasal corticosteroids, bronchodilators, antihistamines, leukotriene receptor antagonists, adrenergics/sympathomimetics and local nasal anaesthetics. There was no indication that the safety of Xolair was altered by the concomitant use of these other commonly used medicinal products.</p><p>&nbsp;</p><p><u>Chronic spontaneous urticaria (CSU)</u></p><p>In clinical studies in CSU, Xolair was used in conjunction with antihistamines (anti-H1, anti-H2) and leukotriene receptor antagonists (LTRAs). There was no evidence that the safety of omalizumab was altered when used with these medicinal products relative to its known safety profile in allergic asthma. In addition, a population pharmacokinetic analysis showed no relevant effect of H2 antihistamines and LTRAs on omalizumab pharmacokinetics (see section 5.2).</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>Clinical studies in CSU included some patients aged 12 to 17&nbsp;years taking Xolair in conjunction with antihistamines (anti-H1, anti-H2) and LTRAs. No studies have been performed in children under 12&nbsp;years.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>A moderate amount of data on pregnant women (between 300‑1,000&nbsp;pregnancy outcomes) based on pregnancy registry and post-marketing spontaneous reports, indicates no malformative or foeto/neonatal toxicity. A prospective pregnancy registry study (EXPECT) in 250&nbsp;pregnant women with asthma exposed to Xolair showed the prevalence of major congenital anomalies was similar (8.1% vs. 8.9%) between EXPECT and disease‑matched (moderate and severe asthma) patients. The interpretation of data may be impacted due to methodological limitations of the study, including small sample size and non-randomised design.</p><p>&nbsp;</p><p>A registry study of XOLAIR exposure during pregnancy showed no increase in the rate of major birth defects or miscarriage. There was an increased rate of low birth weight among registry infants compared to infants in the other cohorts, despite average gestational age at birth; however, women taking XOLAIR during pregnancy also had more severe asthma, which makes it difficult to determine whether the low birth weight is due to the drug or the disease severity. There are risks associated with poorly or moderately controlled asthma in pregnancy. &nbsp;</p><p>&nbsp;</p><p>Omalizumab crosses the placental barrier. However, animal studies do not indicate either direct or indirect harmful effects with respect to reproductive toxicity (see section&nbsp;5.3).</p><p>&nbsp;</p><p>Omalizumab has been associated with age-dependent decreases in blood platelets in non-human primates, with a greater relative sensitivity in juvenile animals (see section&nbsp;5.3).</p><p>&nbsp;</p><p>If clinically needed, the use of Xolair may be considered during pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Immunoglobulins G (IgGs) are present in human milk and therefore it is expected that omalizumab will be present in human milk. Available data in non-human primates have shown excretion of omalizumab into milk (see section&nbsp;5.3).</p><p>The EXPECT study, with 154&nbsp;infants who had been exposed to Xolair during pregnancy and through breast-feeding did not indicate adverse effects on the breast-fed infant. The interpretation of data may be impacted due to methodological limitations of the study, including small sample size and non-randomised design.</p><p>&nbsp;</p><p>Given orally, immunoglobulin G proteins undergo intestinal proteolysis and have poor bioavailability. No effects on the breast-fed newborns/infants are anticipated. Consequently, if clinically needed, the use of Xolair may be considered during breast-feeding.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>There are no human fertility data for omalizumab. In specifically-designed non-clinical fertility studies, including mating studies, no impairment of male or female fertility was observed following repeated dosing with omalizumab at dose levels up to 75&nbsp;mg/kg. Furthermore, no genotoxic effects were observed in separate non-clinical genotoxicity studies (see section 5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Xolair has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Allergic asthma and chronic rhinosinusitis with nasal polyps (</u>CRSwNP<u>)</u></p><p><em><u>Summary of safety profile</u></em></p><p>During allergic asthma clinical trials in adult and adolescent patients 12&nbsp;years of age and older, the most commonly reported adverse reactions were injection site reactions, including injection site pain, swelling, erythema, pruritus and headaches. In clinical trials in children 6 to &lt;12&nbsp;years of age, the most commonly reported adverse reactions &nbsp;were headache, pyrexia and upper abdominal pain. Most of the reactions were mild or moderate in severity.&nbsp;In clinical trials in patients &ge;18&nbsp;years of age in CRSwNP, the most commonly reported adverse reactions were headache, dizziness, arthralgia, abdominal pain upper and injection site reactions.</p><p><em><u>Tabulated list of adverse reactions</u></em></p><p>Table&nbsp;4 lists the adverse reactions recorded in clinical studies in the total allergic asthma and CRSwNP safety population treated with Xolair by MedDRA system organ class and frequency. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. Frequency categories are defined as: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000) and very rare (&lt;1/10,000). Reactions reported in the post-marketing setting are listed with frequency not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p><strong>Table&nbsp;4: Adverse reactions in allergic asthma</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Pharyngitis</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Parasitic infection</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Idiopathic thrombocytopenia, including severe cases</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Anaphylactic reaction, other serious allergic conditions, anti-omalizumab antibody development</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Serum sickness, may include fever and lymphadenopathy</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Headache*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Syncope, paraesthesia, somnolence, dizziness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Postural hypotension, flushing</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Allergic bronchospasm, coughing</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Laryngoedema</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Allergic granulomatous vasculitis (i.e. Churg-Strauss syndrome)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Abdominal pain upper**</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Dyspeptic signs and symptoms, diarrhoea, nausea</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Photosensitivity, urticaria, rash, pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Angioedema</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Alopecia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>common</p><p>rare</p><p>&nbsp;</p><p>Not known</p></td><td style="vertical-align:top"><p>Arthralgia,</p><p>Systemic lupus erythematosus (SLE)</p><p>myalgia, joint swelling</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Pyrexia**</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Injection site reactions such as swelling, erythema, pain, pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Influenza-like illness, swelling arms, weight increase, fatigue</p></td></tr></tbody></table><p>*: Very common in children 6 to &lt;12&nbsp;years of age</p><p>**: In children 6 to &lt;12&nbsp;years of age</p><p><sup>#</sup>: Common in nasal polyp trials</p><p>&dagger;: Unknown in allergic asthma trials</p><p>&nbsp;</p><p><u>Chronic spontaneous urticaria (CSU)</u></p><p><em><u>Summary of safety profile</u></em></p><p>The safety and tolerability of omalizumab were investigated with doses of 75&nbsp;mg, 150&nbsp;mg and 300&nbsp;mg every four weeks in 975&nbsp;CSU patients, 242 of whom received placebo. Overall, 733&nbsp;patients were treated with omalizumab for up to 12&nbsp;weeks and 490&nbsp;patients for up to 24&nbsp;weeks. Of those, 412&nbsp;patients were treated for up to 12&nbsp;weeks and 333&nbsp;patients were treated for up to 24&nbsp;weeks at the 300&nbsp;mg dose.</p><p>&nbsp;</p><p><em><u>Tabulated list of adverse reactions</u></em></p><p>A separate table (Table&nbsp;5) shows the adverse reactions for the CSU indication resulting from differences in dosages and treatment populations (with significantly different risk factors, comorbidities, co-medications and ages [e.g. asthma trials included children from 6‑12&nbsp;years of age]).</p><p>&nbsp;</p><p>Table&nbsp;5 lists the adverse reactions (events occurring in &ge;1% of patients in any treatment group and &ge;2% more frequently in any omalizumab treatment group than with placebo (after medical review)) reported with 300&nbsp;mg in the three pooled phase III studies. The adverse reactions presented are divided into two groups: those identified in the 12‑week and the 24‑week treatment periods.</p><p>&nbsp;</p><p>The adverse reactions are listed by MedDRA system organ class. Within each system organ class, the adverse reactions are ranked by frequency, with the most frequent reactions listed first. The corresponding frequency category for each adverse reaction is based on the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1000); very rare (&lt;1/10,000) and not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p><em>Table&nbsp;5: Adverse reactions from the pooled CSU safety database (day&nbsp;1 to week&nbsp;24) at 300&nbsp;mg omalizumab</em></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2"><p><strong>12-Week</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Omalizumab studies 1, 2 and 3 Pooled</strong></p></td><td style="vertical-align:top"><p><strong>Frequency category</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Placebo N=242</p></td><td><p>300&nbsp;mg N=412</p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Sinusitis</p></td><td style="vertical-align:top"><p>5 (2.1%)</p></td><td><p>20 (4.9%)</p></td><td colspan="2"><p>Common</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Headache</p></td><td style="vertical-align:top"><p>7 (2.9%)</p></td><td><p>25 (6.1%)</p></td><td colspan="2"><p>Common</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Arthralgia</p></td><td style="vertical-align:top"><p>1 (0.4%)</p></td><td><p>12 (2.9%)</p></td><td colspan="2"><p>Common</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>General disorder and administration site conditions</strong></p></td></tr><tr><td><p>Injection site reaction*</p></td><td><p>2 (0.8%)</p></td><td><p>11 (2.7%)</p></td><td colspan="2"><p>Common</p></td></tr><tr><td rowspan="2"><p><strong>24-Week</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Omalizumab studies 1 and 3 Pooled</strong></p></td><td style="vertical-align:top"><p><strong>Frequency category</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Placebo N=163</p></td><td><p>300&nbsp;mg N=333</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Upper respiratory tract infection</p></td><td><p>5 (3.1%)</p></td><td><p>19 (5.7%)</p></td><td colspan="2"><p>Common</p></td></tr></tbody></table><p>* Despite not showing a 2% difference to placebo, injection site reactions were included as all cases were assessed causally related to study treatment.</p><p>&nbsp;</p><p>In a 48 week study, 81 CSU patients received omalizumab 300 mg every 4 weeks (see section 5.1). The safety profile of long-term use was similar to the safety profile observed in 24-week studies in CSU.</p><p>&nbsp;</p><p><em><u>Description of&nbsp;</u></em><u>selected adverse reactions</u></p><p>&nbsp;</p><p><u>Immune system disorders</u></p><p>For further information, see section 4.4.</p><p><em><u>Anaphylaxis</u></em></p><p>Anaphylactic reactions were rare in clinical trials. However, post-marketing data following a cumulative search in the safety database retrieved a total of 898 anaphylaxis cases. Based on an estimated exposure of 566,923 patient treatment years, this results in a reporting rate of approximately 0.20%.</p><p><u>Arterial thromboembolic events (ATE)</u></p><p>In controlled clinical trials and during interim analyses of an observational study, a numerical imbalance of ATE was observed. ATE included stroke, transient ischaemic attack, myocardial infarction, unstable angina, and cardiovascular death (including death from unknown cause). In the final analysis of the observational study, the rate of ATE per 1,000 patient years was 7.52 (115/15,286 patient years) for Xolair-treated patients and 5.12 (51/9,963 patient years) for control patients. In a multivariate analysis controlling for available baseline cardiovascular risk factors, the hazard ratio was 1.32 (95% confidence interval 0.91‑1.91). In a new analysis of pooled clinical trials, which included all randomised double-blind, placebo-controlled clinical trials lasting 8 or more weeks, the rate of ATE per 1,000 patient years was 2.69 (5/1,856 patient years) for Xolair-treated patients and 2.38 (4/1,680 patient years) for placebo patients (rate ratio 1.13, 95% confidence interval 0.24‑5.71).</p><p>&nbsp;</p><p><u>Platelets</u></p><p>In clinical trials few patients had platelet counts below the lower limit of the normal laboratory range. None of these changes were associated with bleeding episodes or a decrease in haemoglobin. No pattern of persistent decrease in platelet counts, as observed in non-human primates (see section 5.3), has been reported in humans (patients above 6&nbsp;years of age), even though isolated cases of idiopathic thrombocytopenia, including severe cases, have been reported in the post-marketing setting.</p><p>&nbsp;</p><p><u>Parasitic infections</u></p><p>In allergic patients at chronic high risk of helminth infection, a placebo-controlled trial showed a slight numerical increase in infection rate with omalizumab that was not statistically significant. The course, severity, and response to treatment of infections were unaltered (see section 4.4).</p><p><em><u>Systemic lupus erythematosus</u></em></p><p>Clinical trial and post-marketing cases of systemic lupus erythematosus (SLE) have been reported in patients with moderate to severe asthma and CSU. The pathogenesis of SLE is not well understood.</p><p><u>Reporting of suspected adverse reactions</u></p><p>To report any side effect(s):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>Fax: +966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa&nbsp;&nbsp;&nbsp;</p><p>Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>&nbsp;</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +966112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>-&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Maximum tolerated dose of Xolair has not been determined. Single intravenous doses up to 4,000&nbsp;mg have been administered to patients without evidence of dose-limiting toxicities. The highest cumulative dose administered to patients was 44,000&nbsp;mg over a 20-week period and this dose did not result in any untoward acute effects.</p><p>&nbsp;</p><p>If an overdose is suspected, the patient should be monitored for any abnormal signs or symptoms. Medical treatment should be sought and instituted appropriately.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Describe the following: </em></p><p>- <em>Pharmacotherapeutic group: </em>Drugs for obstructive airway diseases, other systemic drugs for obstructive airway diseases, ATC code: R03DX05</p><p>&nbsp;</p><p>Omalizumab is a recombinant DNA-derived humanised monoclonal antibody that selectively binds to human immunoglobulin E (IgE). The antibody is an IgG1 kappa that contains human framework regions with the complementary-determining regions of a murine parent antibody that binds to IgE.</p><p>&nbsp;</p><p><u>Allergic asthma&nbsp;and chronic rhinosinusitis with nasal polyps (CRSwNP)</u></p><p><em><u>Mechanism of action</u></em></p><p>Omalizumab binds to IgE and prevents binding of IgE to FCeRI (high-affinity IgE receptor) on basophils and mast cells, thereby reducing the amount of free IgE that is available to trigger the allergic cascade. Treatment of atopic subjects with omalizumab resulted in a marked down-regulation of FCeRI receptors on basophils.</p><p>Treatment with Xolair inhibits IgE-mediated inflammation, as evidenced by reduced blood and tissue eosinophils and reduced inflammatory mediators, including IL‑4, IL-5, and IL-13 by innate, adaptive and non-immune cells.</p><p>&nbsp;</p><p><em><u>Pharmacodynamic effects</u></em></p><p><em>Allergic asthma</em></p><p>the <em>in vitro</em> histamine release from basophils isolated from Xolair-treated subjects was reduced by approximately 90% following stimulation with an allergen compared to pre-treatment values.</p><p>&nbsp;</p><p>In clinical studies in allergic asthma patients, serum free IgE levels were reduced in a dose-dependent manner within one hour following the first dose and maintained between doses. One year after discontinuation of Xolair dosing, the IgE levels had returned to pre-treatment levels with no observed rebound in IgE levels after washout of the medicinal product.</p><p>&nbsp;</p><p><em>Chronic rhinosinusitis with nasal polyps (CRSwNP)</em></p><p>In clinical studies in patients with CRSwNP, Xolair treatment led to a reduction in serum free IgE (approx. 95%) and an increase in serum total IgE levels, to a similar extent as observed in patients with allergic asthma. Total IgE levels in serum increased due to the formation of omalizumab‑IgE complexes that have a slower elimination rate compared with free IgE.</p><p>&nbsp;</p><p><u>Chronic spontaneous urticaria (CSU)</u></p><p><em><u>Mechanism of action</u></em></p><p>Omalizumab binds to IgE and lowers free IgE levels. Subsequently, IgE receptors (Fc&epsilon;RI) on cells down-regulate. It is not entirely understood<em> </em>how this results in an improvement of CSU symptoms.</p><p>&nbsp;</p><p><em><u>Pharmacodynamic effect</u></em></p><p>In clinical studies in CSU patients, maximum suppression of free IgE was observed 3&nbsp;days after the first subcutaneous dose. After repeated dosing once every 4&nbsp;weeks, pre-dose serum free IgE levels remained stable between 12 and 24&nbsp;weeks of treatment. After discontinuation of Xolair, free IgE levels increased towards pre-treatment levels over a 16‑week treatment-free follow-up period.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><em><u>Allergic asthma</u></em></p><p><em><u>Adults and adolescents &ge;12&nbsp;years of age</u></em></p><p>The efficacy and safety of Xolair were demonstrated in a 28-week double-blind placebo-controlled study (study&nbsp;1) involving 419&nbsp;severe allergic asthmatics, ages 12‑79&nbsp;years, who had reduced lung function (FEV<sub>1</sub> 40‑80% predicted) and poor asthma symptom control despite receiving high dose inhaled corticosteroids and a long-acting beta2-agonist. Eligible patients had experienced multiple asthma exacerbations requiring systemic corticosteroid treatment or had been hospitalised or attended an emergency room due to a severe asthma exacerbation in the past year despite continuous treatment with high-dose inhaled corticosteroids and a long-acting beta2-agonist. Subcutaneous Xolair or placebo were administered as add-on therapy to &gt;1,000&nbsp;micrograms beclomethasone dipropionate (or equivalent) plus a long-acting beta2-agonist. Oral corticosteroid, theophylline and leukotriene-modifier maintenance therapies were allowed (22%, 27%, and 35% of patients, respectively).</p><p>&nbsp;</p><p>The rate of asthma exacerbations requiring treatment with bursts of systemic corticosteroids was the primary endpoint. Omalizumab reduced the rate of asthma exacerbations by 19% (p = 0.153). Further evaluations which did show statistical significance (p&lt;0.05) in favour of Xolair included reductions in severe exacerbations (where patient&rsquo;s lung function was reduced to below 60% of personal best and requiring systemic corticosteroids) and asthma-related emergency visits (comprised of hospitalisations, emergency room, and unscheduled doctor visits), and improvements in Physician&rsquo;s overall assessment of treatment effectiveness, Asthma-related Quality of Life (AQL), asthma symptoms and lung function.</p><p>&nbsp;</p><p>In a subgroup analysis, patients with pre-treatment total IgE &ge;76&nbsp;IU/ml were more likely to experience clinically meaningful benefit to Xolair. In these patients in study&nbsp;1 Xolair reduced the rate of asthma exacerbations by 40% (p = 0.002). In addition more patients had clinically meaningful responses in the total IgE &ge;76&nbsp;IU/ml population across the Xolair severe asthma programme. Table&nbsp;6 includes results in the study&nbsp;1 population.</p><p>&nbsp;</p><p><strong>Table&nbsp;6: Results of study&nbsp;1</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Whole study&nbsp;1 population</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Xolair</p><p>N=209</p></td><td style="vertical-align:top"><p>Placebo</p><p>N=210</p></td></tr><tr><td style="vertical-align:top"><p><strong>Asthma exacerbations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rate per 28-week period</p></td><td style="vertical-align:top"><p>0.74</p></td><td style="vertical-align:top"><p>0.92</p></td></tr><tr><td style="vertical-align:top"><p>% reduction, p-value for rate ratio</p></td><td colspan="2" style="vertical-align:top"><p>19.4%, p = 0.153</p></td></tr><tr><td style="vertical-align:top"><p><strong>Severe asthma exacerbations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rate per 28-week period</p></td><td style="vertical-align:top"><p>0.24</p></td><td style="vertical-align:top"><p>0.48</p></td></tr><tr><td style="vertical-align:top"><p>% reduction, p-value for rate ratio</p></td><td colspan="2" style="vertical-align:top"><p>50.1%, p = 0.002</p></td></tr><tr><td style="vertical-align:top"><p><strong>Emergency visits</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rate per 28-week period</p></td><td style="vertical-align:top"><p>0.24</p></td><td style="vertical-align:top"><p>0.43</p></td></tr><tr><td style="vertical-align:top"><p>% reduction, p-value for rate ratio</p></td><td colspan="2" style="vertical-align:top"><p>43.9%, p = 0.038</p></td></tr><tr><td style="vertical-align:top"><p><strong>Physician&rsquo;s overall assessment</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>% responders*</p></td><td style="vertical-align:top"><p>60.5%</p></td><td style="vertical-align:top"><p>42.8%</p></td></tr><tr><td style="vertical-align:top"><p>p-value**</p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p><strong>AQL improvement</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>% of patients &ge;0.5 improvement</p></td><td style="vertical-align:top"><p>60.8%</p></td><td style="vertical-align:top"><p>47.8%</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.008</p></td></tr></tbody></table><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; marked improvement or complete control</p><p>**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p-value for overall distribution of assessment</p><p>&nbsp;</p><p>Study&nbsp;2 assessed the efficacy and safety of Xolair in a population of 312&nbsp;severe allergic asthmatics which matched the population in study&nbsp;1. Treatment with Xolair in this open label study led to a 61% reduction in clinically significant asthma exacerbation rate compared to current asthma therapy alone.</p><p>&nbsp;</p><p>Four additional large placebo-controlled supportive studies of 28 to 52&nbsp;weeks duration in 1,722&nbsp;adults and adolescents (studies&nbsp;3, 4, 5, 6) assessed the efficacy and safety of Xolair in patients with severe persistent asthma. Most patients were inadequately controlled but were receiving less concomitant asthma therapy than patients in studies&nbsp;1 or 2. Studies&nbsp;3‑5 used exacerbation as primary endpoint, whereas study&nbsp;6 primarily evaluated inhaled corticosteroid sparing.</p><p>&nbsp;</p><p>In studies&nbsp;3, 4 and 5 patients treated with Xolair had respective reductions in asthma exacerbation rates of 37.5% (p = 0.027), 40.3% (p&lt;0.001) and 57.6% (p&lt;0.001) compared to placebo.</p><p>&nbsp;</p><p>In study&nbsp;6, significantly more severe allergic asthma patients on Xolair were able to reduce their fluticasone dose to &pound;500&nbsp;micrograms/day without deterioration of asthma control (60.3%) compared to the placebo group (45.8%, p&lt;0.05).</p><p>&nbsp;</p><p>Quality of life scores were measured using the Juniper Asthma-related Quality of Life Questionnaire. For all six studies there was a statistically significant improvement from baseline in quality of life scores for Xolair patients versus the placebo or control group.</p><p>&nbsp;</p><p>Physician&rsquo;s overall assessment of treatment effectiveness:</p><p>Physician&rsquo;s overall assessment was performed in five of the above studies as a broad measure of asthma control performed by the treating physician. The physician was able to take into account PEF (peak expiratory flow), day and night time symptoms, rescue medication use, spirometry and exacerbations. In all five studies a significantly greater proportion of Xolair treated patients were judged to have achieved either a marked improvement or complete control of their asthma compared to placebo patients.</p><p><u>&nbsp;</u></p><p><em><u>Children 6 to &lt;12&nbsp;years of age</u></em></p><p>The primary support for safety and efficacy of Xolair in the group aged 6 to &lt;12&nbsp;years comes from one randomised, double-blind, placebo-controlled, multi-centre trial (study&nbsp;7).</p><p>&nbsp;</p><p>Study&nbsp;7 was a placebo-controlled trial which included a specific subgroup (n=235) of patients as defined in the present indication, who were treated with high-dose inhaled corticosteroids (&ge;500&nbsp;&micro;g/day fluticasone equivalent) plus long-acting beta agonist.</p><p>&nbsp;</p><p>A clinically significant exacerbation was defined as a worsening of asthma symptoms as judged clinically by the investigator, requiring doubling of the baseline inhaled corticosteroid dose for at least 3&nbsp;days and/or treatment with rescue systemic (oral or intravenous) corticosteroids for at least 3&nbsp;days.</p><p>&nbsp;</p><p>In the specific subgroup of patients on high dose inhaled corticosteroids, the omalizumab group had a statistically significantly lower rate of clinically significant asthma exacerbations than the placebo group. At 24&nbsp;weeks, the difference in rates between treatment groups represented a 34% (rate ratio 0.662, p = 0.047) decrease relative to placebo for omalizumab patients. In the second double-blind 28-week treatment period the difference in rates between treatment groups represented a 63% (rate ratio 0.37, p&lt;0.001) decrease relative to placebo for omalizumab patients.</p><p>&nbsp;</p><p>During the 52-week double-blind treatment period (including the 24-week fixed-dose steroid phase and the 28-week steroid adjustment phase) the difference in rates between treatment groups represented a 50% (rate ratio 0.504, p&lt;0.001) relative decrease in exacerbations for omalizumab patients.</p><p>&nbsp;</p><p>The omalizumab group showed greater decreases in beta-agonist rescue medication use than the placebo group at the end of the 52-week treatment period, although the difference between treatment groups was not statistically significant. For the global evaluation of treatment effectiveness at the end of the 52-week double-blind treatment period in the subgroup of severe patients on high-dose inhaled corticosteroids plus long-acting beta agonists, the proportion of patients rated as having &lsquo;excellent&rsquo; treatment effectiveness was higher, and the proportions having &lsquo;moderate&rsquo; or &lsquo;poor&rsquo; treatment effectiveness lower in the omalizumab group compared to the placebo group; the difference between groups was statistically significant (p&lt;0.001), while there were no differences between the omalizumab and placebo groups for patients&rsquo; subjective Quality of Life ratings.</p><p>&nbsp;</p><p><em><u>Chronic rhinosinusitis with nasal polyps (CRSwNP)</u></em></p><p>The safety and efficacy of Xolair were evaluated in two randomised, double-blind, placebo-controlled trials in patients with CRSwNP (Table&nbsp;8). Patients received Xolair or placebo subcutaneously every 2 or 4&nbsp;weeks (see section&nbsp;4.2). All patients received background intranasal mometasone therapy throughout the study. Prior sino-nasal surgery or prior systemic corticosteroid usage were not required for inclusion in the studies. Patients received Xolair or placebo for 24&nbsp;weeks followed by a 4-week follow-up period. Demographics and baseline characteristics, including allergic comorbidities, are described in Table&nbsp;7.</p><p><strong>Table&nbsp;7 Demographics and baseline characteristics of nasal polyp studies</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Parameter</strong></p></td><td style="vertical-align:top"><p><strong>Nasal polyp study&nbsp;1</strong></p><p><strong>N=138</strong></p></td><td style="vertical-align:top"><p><strong>Nasal polyp study&nbsp;2</strong></p><p><strong>N=127</strong></p></td></tr><tr><td style="vertical-align:top"><p>Mean age (years) (SD)</p></td><td style="vertical-align:top"><p>51.0 (13.2)</p></td><td style="vertical-align:top"><p>50.1 (11.9)</p></td></tr><tr><td style="vertical-align:top"><p>% Male</p></td><td style="vertical-align:top"><p>63.8</p></td><td style="vertical-align:top"><p>65.4</p></td></tr><tr><td style="vertical-align:top"><p>Patients with systemic corticosteroid use in the previous year (%)</p></td><td style="vertical-align:top"><p>18.8</p></td><td style="vertical-align:top"><p>26.0</p></td></tr><tr><td style="vertical-align:top"><p>Bilateral endoscopic nasal polyp score (NPS): mean (SD), range 0-8</p></td><td style="vertical-align:top"><p>6.2 (1.0)</p></td><td style="vertical-align:top"><p>6.3 (0.9)</p></td></tr><tr><td style="vertical-align:top"><p>Nasal congestion score (NCS): mean (SD), range 0-3</p></td><td style="vertical-align:top"><p>2.4 (0.6)</p></td><td style="vertical-align:top"><p>2.3 (0.7)</p></td></tr><tr><td style="vertical-align:top"><p>Sense of smell score: mean (SD), range 0-3</p></td><td style="vertical-align:top"><p>2.7 (0.7)</p></td><td style="vertical-align:top"><p>2.7 (0.7)</p></td></tr><tr><td style="vertical-align:top"><p>SNOT-22 total score: mean (SD) range 0-110</p></td><td style="vertical-align:top"><p>60.1 (17.7)</p></td><td style="vertical-align:top"><p>59.5 (19.3)</p></td></tr><tr><td style="vertical-align:top"><p>Blood eosinophils (cells/&micro;l): mean (SD)</p></td><td style="vertical-align:top"><p>346.1 (284.1)</p></td><td style="vertical-align:top"><p>334.6 (187.6)</p></td></tr><tr><td style="vertical-align:top"><p>Total IgE IU/ml: mean (SD)</p></td><td style="vertical-align:top"><p>160.9 (139.6)</p></td><td style="vertical-align:top"><p>190.2 (200.5)</p></td></tr><tr><td style="vertical-align:top"><p>Asthma (%)</p></td><td style="vertical-align:top"><p>53.6</p></td><td style="vertical-align:top"><p>60.6</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Mild (%)</p></td><td style="vertical-align:top"><p>37.8</p></td><td style="vertical-align:top"><p>32.5</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Moderate (%)</p></td><td style="vertical-align:top"><p>58.1</p></td><td style="vertical-align:top"><p>58.4</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Severe (%)</p></td><td style="vertical-align:top"><p>4.1</p></td><td style="vertical-align:top"><p>9.1</p></td></tr><tr><td style="vertical-align:top"><p>Aspirin exacerbated respiratory disease (%)</p></td><td style="vertical-align:top"><p>19.6</p></td><td style="vertical-align:top"><p>35.4</p></td></tr><tr><td style="vertical-align:top"><p>Allergic rhinitis</p></td><td style="vertical-align:top"><p>43.5</p></td><td style="vertical-align:top"><p>42.5</p></td></tr></tbody></table><p>SD = standard deviation; SNOT-22 = Sino-Nasal Outcome Test 22 Questionnaire; IgE = Immunoglobulin E; IU = international units. For NPS, NCS, and SNOT-22 higher scores indicate greater disease severity.</p><p>&nbsp;</p><p>The co-primary endpoints were bilateral nasal polyps score (NPS) and average daily nasal congestion score (NCS) at Week&nbsp;24. In both nasal polyp studies&nbsp;1 and 2, patients who received Xolair had statistically significant greater improvements from baseline at Week&nbsp;24 in NPS and weekly average NCS than patients who received placebo. Results from nasal polyp studies&nbsp;1 and 2 are shown in Table&nbsp;8.</p><p>&nbsp;</p><p><strong>Table&nbsp;8 Change from baseline at Week&nbsp;24 in clinical scores from nasal polyp study</strong><strong>&nbsp;1, nasal polyp study</strong><strong>&nbsp;2, and pooled data</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:98%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Nasal polyp<br />study&nbsp;1</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Nasal polyp<br />study&nbsp;2</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Nasal polyp<br />pooled results</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p><strong>Placebo</strong></p></td><td style="vertical-align:bottom"><p><strong>Xolair</strong></p></td><td style="vertical-align:bottom"><p><strong>Placebo</strong></p></td><td style="vertical-align:bottom"><p><strong>Xolair</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>Xolair</strong></p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>66</p></td><td style="vertical-align:top"><p>72</p></td><td style="vertical-align:top"><p>65</p></td><td style="vertical-align:top"><p>62</p></td><td style="vertical-align:top"><p>131</p></td><td style="vertical-align:top"><p>134</p></td></tr><tr><td style="vertical-align:top"><p>Nasal polyp score</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Baseline mean</p></td><td style="vertical-align:top"><p>6.32</p></td><td style="vertical-align:top"><p>6.19</p></td><td style="vertical-align:top"><p>6.09</p></td><td style="vertical-align:top"><p>6.44</p></td><td style="vertical-align:top"><p>6.21</p></td><td style="vertical-align:top"><p>6.31</p></td></tr><tr><td style="vertical-align:top"><p>LS mean change at Week&nbsp;24</p></td><td style="vertical-align:top"><p>0.06</p></td><td style="vertical-align:top"><p>-1.08</p></td><td style="vertical-align:top"><p>-0.31</p></td><td style="vertical-align:top"><p>-0.90</p></td><td style="vertical-align:top"><p>-0.13</p></td><td style="vertical-align:top"><p>-0.99</p></td></tr><tr><td style="vertical-align:top"><p>Difference (95%) CI<sup> </sup></p></td><td colspan="2" style="vertical-align:top"><p>-1.14 (-1.59, -0.69)</p><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>-0.59 (-1.05, -0.12)</p><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>-0.86 (-1.18, -0.54)</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td><td colspan="2" style="vertical-align:top"><p>0.0140</p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td><p>7-day average of daily nasal congestion score</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Baseline mean</p></td><td style="vertical-align:top"><p>2.46</p></td><td style="vertical-align:top"><p>2.40</p></td><td style="vertical-align:top"><p>2.29</p></td><td style="vertical-align:top"><p>2.26</p></td><td style="vertical-align:top"><p>2.38</p></td><td style="vertical-align:top"><p>2.34</p></td></tr><tr><td style="vertical-align:top"><p>LS mean change at Week&nbsp;24</p></td><td style="vertical-align:top"><p>-0.35</p></td><td style="vertical-align:top"><p>-0.89</p></td><td style="vertical-align:top"><p>-0.20</p></td><td style="vertical-align:top"><p>-0.70</p></td><td style="vertical-align:top"><p>-0.28</p></td><td style="vertical-align:top"><p>-0.80</p></td></tr><tr><td style="vertical-align:top"><p>Difference (95%) CI</p></td><td colspan="2" style="vertical-align:top"><p>-0.55 (-0.84, -0.25)</p><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>-0.50 (-0.80, -0.19)</p><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>-0.52 (-0.73, -0.31)</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.0004</p></td><td colspan="2" style="vertical-align:top"><p>0.0017</p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>TNSS</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Baseline mean</p></td><td style="vertical-align:top"><p>9.33</p></td><td style="vertical-align:top"><p>8.56</p></td><td style="vertical-align:top"><p>8.73</p></td><td style="vertical-align:top"><p>8.37</p></td><td style="vertical-align:top"><p>9.03</p></td><td style="vertical-align:top"><p>8.47</p></td></tr><tr><td style="vertical-align:top"><p>LS mean change at Week&nbsp;24</p></td><td style="vertical-align:top"><p>-1.06</p></td><td style="vertical-align:top"><p>-2.97</p></td><td style="vertical-align:top"><p>-0.44</p></td><td style="vertical-align:top"><p>-2.53</p></td><td style="vertical-align:top"><p>-0.77</p></td><td style="vertical-align:top"><p>-2.75</p></td></tr><tr><td style="vertical-align:top"><p>Difference (95%)</p></td><td colspan="2" style="vertical-align:top"><p>-1.91 (-2.85, -0.96)</p></td><td colspan="2" style="vertical-align:top"><p>-2.09 (-3.00, -1.18)</p></td><td colspan="2" style="vertical-align:top"><p>-1.98 (-2.63, -1.33)</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.0001</p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>SNOT-22</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Baseline mean</p></td><td style="vertical-align:top"><p>60.26</p></td><td style="vertical-align:top"><p>59.82</p></td><td style="vertical-align:top"><p>59.80</p></td><td style="vertical-align:top"><p>59.21</p></td><td style="vertical-align:top"><p>60.03</p></td><td style="vertical-align:top"><p>59.54</p></td></tr><tr><td style="vertical-align:top"><p>LS mean change at Week&nbsp;24</p></td><td style="vertical-align:top"><p>-8.58</p></td><td style="vertical-align:top"><p>-24.70</p></td><td style="vertical-align:top"><p>-6.55</p></td><td style="vertical-align:top"><p>-21.59</p></td><td style="vertical-align:top"><p>-7.73</p></td><td style="vertical-align:top"><p>-23.10</p></td></tr><tr><td style="vertical-align:top"><p>Difference (95%)</p></td><td colspan="2" style="vertical-align:top"><p>-16.12 (-21.86, -10.38)</p></td><td colspan="2" style="vertical-align:top"><p>-15.04 (-21.26, -8.82)</p></td><td colspan="2" style="vertical-align:top"><p>-15.36 (-19.57, -11.16)</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>(MID = 8.9)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>UPSIT</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Baseline mean</p></td><td style="vertical-align:top"><p>13.56</p></td><td style="vertical-align:top"><p>12.78</p></td><td style="vertical-align:top"><p>13.27</p></td><td style="vertical-align:top"><p>12.87</p></td><td style="vertical-align:top"><p>13.41</p></td><td style="vertical-align:top"><p>12.82</p></td></tr><tr><td style="vertical-align:top"><p>LS mean change at Week&nbsp;24</p></td><td style="vertical-align:top"><p>0.63</p></td><td style="vertical-align:top"><p>4.44</p></td><td style="vertical-align:top"><p>0.44</p></td><td style="vertical-align:top"><p>4.31</p></td><td style="vertical-align:top"><p>0.54</p></td><td style="vertical-align:top"><p>4.38</p></td></tr><tr><td style="vertical-align:top"><p>Difference (95%)</p></td><td colspan="2" style="vertical-align:top"><p>3.81 (1.38, 6.24)</p></td><td colspan="2" style="vertical-align:top"><p>3.86 (1.57, 6.15)</p></td><td colspan="2" style="vertical-align:top"><p>3.84 (2.17, 5.51)</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.0024</p></td><td colspan="2" style="vertical-align:top"><p>0.0011</p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td></tr></tbody></table><p>LS=least-square; CI = confidence interval; TNSS = Total nasal symptom score; SNOT-22 = Sino-Nasal Outcome Test 22 Questionnaire; UPSIT = University of Pennsylvania Smell Identification Test; MID = minimal important difference.</p><p>&nbsp;</p><p><strong>&nbsp; &nbsp;</strong><strong>Figure&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='background:yellow;mso-highlight:
yellow;font-style:normal;mso-bidi-font-style:italic'><span style='mso-element:
field-begin'></span><span style='mso-spacerun:yes'>  </span>SEQ Figure \s 1 \*
ARABIC<span style='mso-spacerun:yes'>  </span>\* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>1</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='background:yellow;mso-highlight:
yellow;font-style:normal;mso-bidi-font-style:italic'><span style='mso-element:
field-end'></span></span></b><![endif]--><strong>&nbsp;&nbsp;&nbsp; Mean change from baseline in nasal congestion score and mean change from baseline in nasal polyp score by treatment group in nasal polyp study&nbsp;1 and study&nbsp;2</strong></p><p><img alt="" width="769" height="373" src="data:image/png;base64,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" /></p><p>In a pre-specified pooled analysis of rescue treatment (systemic corticosteroids for &sup3;3&nbsp;consecutive days or nasal polypectomy) during the 24-week treatment period, the proportion of patients requiring rescue treatment was lower in Xolair compared to placebo (2.3% versus 6.2%, respectively). The odds-ratio of having taken rescue treatment in Xolair compared to placebo was 0.38 (95% CI: 0.10, 1.49). There were no sino-nasal surgeries reported in either study.</p><p>&nbsp;</p><p>The long-term efficacy and safety of Xolair in patients with CRSwNP who had participated in nasal polyp studies&nbsp;1 and 2 was assessed in an open-label extension study. Efficacy data from this study suggest that clinical benefit provided at Week&nbsp;24 was sustained through to Week&nbsp;52. Safety data were overall consistent with the known safety profile of omalizumab.</p><p>&nbsp;</p><p><u>Clinical experience in chronic spontaneous urticaria (CSU)</u></p><p>The efficacy and safety of Xolair were demonstrated in two randomised, placebo-controlled phase III studies (study&nbsp;1 and 2) in patients with CSU who remained symptomatic despite H1 antihistamine therapy at the approved dose. A third study (study&nbsp;3) primarily evaluated the safety of Xolair in patients with CSU who remained symptomatic despite treatment with H1 antihistamines at up to four times the approved dose and H2 antihistamine and/or LTRA treatment. The three studies enrolled 975&nbsp;patients aged between 12 and 75&nbsp;years (mean age 42.3&nbsp;years; 39&nbsp;patients 12‑17&nbsp;years, 54&nbsp;patients &ge;65&nbsp;years; 259&nbsp;males and 716&nbsp;females). All patients were required to have inadequate symptom control, as assessed by a weekly urticaria activity score (UAS7, range 0‑42) of &ge;16, and a weekly itch severity score (which is a component of the UAS7; range 0‑21) of &ge;8 for the 7&nbsp;days prior to randomisation, despite having used an antihistamine for at least 2&nbsp;weeks beforehand.</p><p>&nbsp;</p><p>In studies&nbsp;1 and 2, patients had a mean weekly itch severity score of between 13.7 and 14.5 at baseline and a mean UAS7 score of 29.5 and 31.7 respectively. Patients in safety study&nbsp;3 had a mean weekly itch severity score of 13.8 and a mean UAS7 score of 31.2 at baseline. Across all three studies, patients reported receiving on average 4 to 6&nbsp;medications (including H1 antihistamines) for CSU symptoms prior to study enrollment. Patients received Xolair at 75&nbsp;mg, 150&nbsp;mg or 300&nbsp;mg or placebo by subcutaneous injection every 4&nbsp;weeks for 24 and 12&nbsp;weeks in studies&nbsp;1 and 2, respectively, and 300&nbsp;mg or placebo by subcutaneous injection every 4&nbsp;weeks for 24&nbsp;weeks in study&nbsp;3. All studies had a 16‑week treatment-free follow-up period.</p><p><u>&nbsp;</u></p><p>The primary endpoint was the change from baseline to week&nbsp;12 in weekly itch severity score. Omalizumab at 300&nbsp;mg reduced the weekly itch severity score by 8.55 to 9.77 (p &lt;0.0001) compared to a reduction of 3.63 to 5.14 for placebo (see Table&nbsp;7). Statistically significant results were further observed in the responder rates for UAS7&le;6 (at week&nbsp;12) which were higher for the 300&nbsp;mg treatment groups, ranging from 52‑66% (p&lt;0.0001) compared to 11‑19% for the placebo groups, and complete response (UAS7=0) was achieved by 34‑44% (p&lt;0.0001) of patients treated with 300&nbsp;mg compared to 5‑9% of patients in the placebo groups. Patients in the 300&nbsp;mg treatment groups achieved the highest mean proportion of angioedema-free days from week&nbsp;4 to week&nbsp;12, (91.0‑96.1%; p&lt;0.001) compared to the placebo groups (88.1‑89.2%). Mean change from baseline to week&nbsp;12 in the overall DLQI for the 300&nbsp;mg treatment groups was greater (p&lt;0.001) than for placebo showing an improvement ranging from 9.7‑10.3&nbsp;points compared to 5.1‑6.1&nbsp;points for the corresponding placebo groups.</p><p><em>&nbsp;</em></p><p><em>Table 9: Change from baseline to week&nbsp;12 in weekly itch severity score, studies&nbsp;1, 2 and 3 (mITT population*)</em></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:80%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p><strong>Placebo</strong></p></td><td style="vertical-align:bottom"><p><strong>Omalizumab<br />300&nbsp;mg</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Study&nbsp;1</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; N</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>81</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Mean (SD)</p></td><td style="vertical-align:top"><p>&minus;3.63 (5.22)</p></td><td style="vertical-align:top"><p>&minus;9.40 (5.73)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Difference in LS means vs. placebo<sup>1</sup></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&minus;5.80</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; 95% CI for difference</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&minus;7.49,&minus;4.10</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; P-value vs. placebo<sup>2</sup></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Study&nbsp;2</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; N</p></td><td style="vertical-align:top"><p>79</p></td><td style="vertical-align:top"><p>79</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Mean (SD)</p></td><td style="vertical-align:top"><p>&minus;5.14 (5.58)</p></td><td style="vertical-align:top"><p>&minus;9.77 (5.95)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Difference in LS means vs. placebo<sup>1</sup></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&minus;4.81</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; 95% CI for difference</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&minus;6.49,&minus;3.13</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; P-value vs. placebo<sup>2</sup></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Study&nbsp;3</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; N</p></td><td style="vertical-align:top"><p>83</p></td><td style="vertical-align:top"><p>252</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Mean (SD)</p></td><td style="vertical-align:top"><p>&minus;4.01 (5.87)</p></td><td style="vertical-align:top"><p>&minus;8.55 (6.01)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Difference in LS means vs. placebo<sup>1</sup></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>‑4.52</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; 95% CI for difference</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&minus;5.97, &minus;3.08</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; P-value vs. placebo<sup>2</sup></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td></tr></tbody></table><p>*Modified intent-to-treat (mITT) population: included all patients who were randomised and received at least one dose of study medication.</p><p>BOCF (Baseline Observation Carried Forward) was used to impute missing data.</p><p><sup>1</sup> The LS mean was estimated using an ANCOVA model. The strata were baseline weekly itch severity score (&lt;13 vs. &ge;13) and baseline weight (&lt;80&nbsp;kg vs. &ge;80&nbsp;kg).</p><p><sup>2</sup> p-value is derived from ANCOVA t-test.</p><p>&nbsp;</p><p>Figure 2 shows the mean weekly itch severity score over time in study&nbsp;1. The mean weekly itch severity scores significantly decreased with a maximum effect around week&nbsp;12 that was sustained over the 24‑week treatment period. The results were similar in study&nbsp;3.</p><p>&nbsp;</p><p>In all three studies the mean weekly itch severity score increased gradually during the 16‑week treatment-free follow-up period, consistent with symptom re-occurrence. Mean values at the end of the follow-up period were similar to the placebo group, but lower than respective mean baseline values.</p><p><em>&nbsp;</em></p><p><em>Figure 2:&nbsp;Mean weekly itch severity score over time, study&nbsp;1 (mITT population)</em></p><p><img alt="" width="789" height="473" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;margin-left:397.85pt;
 margin-top:273.2pt;width:47.25pt;height:20.15pt;z-index:251663360;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" stroked="f"/><v:group id="Group_x0020_4" o:spid="_x0000_s1028" style='position:absolute;
 margin-left:37.25pt;margin-top:-.45pt;width:425.05pt;height:239.05pt;
 z-index:251659264' coordorigin="2163,3977" coordsize="8501,4781" o:gfxdata="UEsDBBQABgAIAAAAIQB9++EIUQEAAFMEAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKyUTW7CMBCF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">
 <v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75"
  o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="Chart_x0020_2" o:spid="_x0000_s1029" type="#_x0000_t75"
  style='position:absolute;left:2163;top:3977;width:8506;height:4637;
  visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:imagedata src="file:///C:/Users/alghasu1/AppData/Local/Temp/7/msohtmlclip1/01/clip_image001.png"
   o:title=""/>
  <o:lock v:ext="edit" aspectratio="f"/>
 </v:shape><v:shapetype id="_x0000_t68" coordsize="21600,21600" o:spt="68"
  adj="5400,5400" path="m0@0l@1@0@1,21600@2,21600@2@0,21600@0,10800,xe">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="val #0"/>
   <v:f eqn="val #1"/>
   <v:f eqn="sum 21600 0 #1"/>
   <v:f eqn="prod #0 #1 10800"/>
   <v:f eqn="sum #0 0 @3"/>
  </v:formulas>
  <v:path o:connecttype="custom" o:connectlocs="10800,0;0,@0;10800,21600;21600,@0"
   o:connectangles="270,180,90,0" textboxrect="@1,@4,@2,21600"/>
  <v:handles>
   <v:h position="#1,#0" xrange="0,10800" yrange="0,21600"/>
  </v:handles>
 </v:shapetype><v:shape id="Up_x0020_Arrow_x0020_5" o:spid="_x0000_s1030"
  type="#_x0000_t68" style='position:absolute;left:2610;top:8332;width:161;
  height:426;visibility:visible;mso-wrap-style:square;v-text-anchor:top'
  o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" adj="4148" fillcolor="black" stroked="f">
  <v:stroke joinstyle="round"/>
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><o:p>&nbsp;</o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="Up_x0020_Arrow_x0020_6" o:spid="_x0000_s1031" type="#_x0000_t68"
  style='position:absolute;left:4126;top:8332;width:160;height:426;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" adj="4148" fillcolor="black" stroked="f">
  <v:stroke joinstyle="round"/>
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><o:p>&nbsp;</o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="Up_x0020_Arrow_x0020_8" o:spid="_x0000_s1032" type="#_x0000_t68"
  style='position:absolute;left:4918;top:8332;width:161;height:426;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" adj="4148" fillcolor="black" stroked="f">
  <v:stroke joinstyle="round"/>
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><o:p>&nbsp;</o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="Up_x0020_Arrow_x0020_9" o:spid="_x0000_s1033" type="#_x0000_t68"
  style='position:absolute;left:5694;top:8332;width:160;height:426;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" adj="4148" fillcolor="black" stroked="f">
  <v:stroke joinstyle="round"/>
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><o:p>&nbsp;</o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="Up_x0020_Arrow_x0020_10" o:spid="_x0000_s1034" type="#_x0000_t68"
  style='position:absolute;left:6419;top:8332;width:160;height:426;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" adj="4148" fillcolor="black" stroked="f">
  <v:stroke joinstyle="round"/>
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><o:p>&nbsp;</o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="Up_x0020_Arrow_x0020_11" o:spid="_x0000_s1035" type="#_x0000_t68"
  style='position:absolute;left:3377;top:8332;width:160;height:426;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQA4MxrSwgAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Bi8Iw
EIXvC/6HMIK3Na2ISjWKCKLCXqp72dvYjE2xmZQmav33G0HwNsN78743i1Vna3Gn1leOFaTDBARx
4XTFpYLf0/Z7BsIHZI21Y1LwJA+rZe9rgZl2D87pfgyliCHsM1RgQmgyKX1hyKIfuoY4ahfXWgxx
bUupW3zEcFvLUZJMpMWKI8FgQxtDxfV4swqu5i9PDul4vxuf8nPzM5lNI1epQb9bz0EE6sLH/L7e
61g/hdcvcQC5/AcAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAAAAAA
AAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAALAAAA
AAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQA4MxrSwgAAANsAAAAPAAAA
AAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA9gIAAAAA
" adj="4148" fillcolor="black" stroked="f">
  <v:stroke joinstyle="round"/>
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><o:p>&nbsp;</o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape></v:group><v:shape id="Text_x0020_Box_x0020_12" o:spid="_x0000_s1036"
 type="#_x0000_t202" style='position:absolute;margin-left:146.6pt;margin-top:3.95pt;
 width:60.75pt;height:48pt;z-index:251660288;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal align=center style='text-align:center'><span
    style='mso-bidi-font-size:11.0pt'>Week&nbsp;12 Primary Endpoint<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:shape><v:shape id="Text_x0020_Box_x0020_13" o:spid="_x0000_s1037" type="#_x0000_t202"
 style='position:absolute;margin-left:348.75pt;margin-top:31.75pt;width:113.55pt;
 height:31.45pt;z-index:251661312;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span style='mso-bidi-font-size:11.0pt'>Omalizumab 300&nbsp;mg<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:shape><v:shape id="Text_x0020_Box_x0020_3" o:spid="_x0000_s1027" type="#_x0000_t202"
 style='position:absolute;margin-left:18.45pt;margin-top:50.8pt;width:33.65pt;
 height:161.8pt;z-index:251662336;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f">
 <v:textbox style='layout-flow:vertical;mso-layout-flow-alt:bottom-to-top'>
  <![if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal>Mean weekly itch severity score <o:p></o:p></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]></v:textbox>
</v:shape><v:shape id="Text_x0020_Box_x0020_15" o:spid="_x0000_s1039" type="#_x0000_t202"
 style='position:absolute;margin-left:348.75pt;margin-top:10.75pt;width:66pt;
 height:21pt;z-index:251665408;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span style='mso-bidi-font-size:11.0pt'>Placebo<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:shape><v:shape id="Text_x0020_Box_x0020_14" o:spid="_x0000_s1038" type="#_x0000_t202"
 style='position:absolute;margin-left:56.6pt;margin-top:246.7pt;width:210.75pt;
 height:20.15pt;z-index:251664384;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" stroked="f"/><![endif]--></p><table cellpadding="0" cellspacing="0" align="left" style="width:278.258px"><tbody><tr><td style="width:1px">&nbsp;</td><td style="width:1px">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>The magnitude of the efficacy outcomes observed at week&nbsp;24 of treatment was comparable to that observed at week&nbsp;12:</p><p>For 300&nbsp;mg, in studies&nbsp;1 and 3, the mean decrease from baseline in weekly itch severity score was 9.8 and 8.6, the proportion of patients with UAS7&le;6 was 61.7% and 55.6%, and the proportion of patients with complete response (UAS7=0) was 48.1% and 42.5%, respectively, (all p&lt;0.0001, when compared to placebo).</p><p>&nbsp;</p><p>Clinical trial data on adolescents (12 to 17&nbsp;years) included a total of 39&nbsp;patients, of whom 11 received the 300&nbsp;mg dose. Results for the 300&nbsp;mg are available for 9&nbsp;patients at week&nbsp;12 and 6&nbsp;patients at week&nbsp;24, and show a similar magnitude of response to omalizumab treatment compared to the adult population. Mean change from baseline in weekly itch severity score showed a reduction of 8.25 at week&nbsp;12 and of 8.95 at week&nbsp;24. The responder rates were: 33% at week&nbsp;12 and 67% at week&nbsp;24 for UAS7=0, and 56% at week&nbsp;12 and 67% at week&nbsp;24 for UAS7&le;6.</p><p>&nbsp;</p><p>In a 48 week study, 206 patients aged between 14 and 75 years were enrolled into a 24 week open label treatment period of omalizumab 300 mg every 4 weeks. Patients who responded to treatment in this open label period were then randomised to receive omalizumab 300 mg (81 patients) or placebo (53 patients) every 4 weeks for an additional 24 weeks.</p><p><br />Of the patients who remained on omalizumab treatment for 48 weeks, 21% experienced clinical worsening (UAS7 score 12 for at least 2 consecutive weeks post randomisation between weeks 24 and 48), versus 60.4% of those treated with placebo at week 48 (difference ˗39.4%, p&lt;0.0001, 95% CI: &minus;54.5%, &minus;22.5%).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of omalizumab have been studied in adult and adolescent patients with allergic asthma as well as in adult and adolescent patients with CSU. The general pharmacokinetic characteristics of omalizumab are similar in these populations.</p><p>&nbsp;</p><p>1.1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Absorption</u></p><p>After subcutaneous administration, omalizumab is absorbed with an average absolute bioavailability of 62%. Following a single subcutaneous dose in adult and adolescent patients with asthma or CSU, omalizumab was absorbed slowly, reaching peak serum concentrations after an average of 6‑8&nbsp;days. In patients with asthma, following multiple doses of omalizumab, areas under the serum concentration-time curve from Day&nbsp;0 to Day&nbsp;14 at steady state were up to 6-fold of those after the first dose.</p><p>&nbsp;</p><p>The pharmacokinetics of omalizumab are linear at doses greater than 0.5&nbsp;mg/kg. Following doses of 75&nbsp;mg, 150&nbsp;mg or 300&nbsp;mg every 4&nbsp;weeks in patients with CSU, trough serum concentrations of omalizumab increased proportionally with the dose level.</p><p>&nbsp;</p><p>Administration of Xolair manufactured as a lyophilised or liquid formulation resulted in similar serum concentration-time profiles of omalizumab.</p><p>&nbsp;</p><p>1.1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Distribution</u></p><p><em>In vitro</em>, omalizumab forms complexes of limited size with IgE. Precipitating complexes and complexes larger than one million Daltons in molecular weight are not observed <em>in vitro</em> or <em>in vivo</em>. Based on population pharmacokinetics, distribution of omalizumab was similar in patients with allergic asthma and patients with CSU. The apparent volume of distribution in patients with asthma following subcutaneous administration was 78&nbsp;&plusmn;&nbsp;32&nbsp;ml/kg.</p><p>&nbsp;</p><p>1.1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Elimination</u></p><p>Clearance of omalizumab involves IgG clearance processes as well as clearance via specific binding and complex formation with its target ligand, IgE. Liver elimination of IgG includes degradation in the reticuloendothelial system and endothelial cells. Intact IgG is also excreted in bile. In asthma patients the omalizumab serum elimination half-life averaged 26&nbsp;days, with apparent clearance averaging 2.4&nbsp;&plusmn;&nbsp;1.1&nbsp;ml/kg/day. Doubling of body weight approximately doubled apparent clearance. In CSU patients, based on population pharmacokinetic simulations, omalizumab serum elimination half-life at steady state averaged 24&nbsp;days and apparent clearance at steady state for a patient of 80&nbsp;kg weight was 3.0&nbsp;ml/kg/day.</p><p>&nbsp;</p><p>1.1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Characteristics in patient populations</u></p><p><em><u>Age, Race/Ethnicity, Gender, Body Mass Index</u></em></p><p><em>Patients with asthma&nbsp;and chronic rhinosinusitis with nasal polyps (CRSwNP)</em></p><p>&nbsp;The population pharmacokinetics of omalizumab were analysed to evaluate the effects of demographic characteristics. Analyses of these limited data suggest that no dose adjustments are necessary in patients with asthma for age (6‑76&nbsp;years for patients with allergic asthma; 18 to 75&nbsp;years for patients with CRSwNP), race/ethnicity, gender or body mass index (see section 4.2).</p><p>&nbsp;</p><p><em>Patients with CSU: </em>The effects of demographic characteristics and other factors on omalizumab exposure were evaluated based on population pharmacokinetics. In addition, covariate effects were evaluated by analysing the relationship between omalizumab concentrations and clinical responses. These analyses suggest that no dose adjustments are necessary in patients with CSU for age (12‑75&nbsp;years), race/ethnicity, gender, body weight, body mass index, baseline IgE, anti-FceRI autoantibodies or concomitant use of H2 antihistamines or LTRAs.</p><p><em>&nbsp;</em></p><p><em><u>Renal and hepatic impairment</u></em></p><p>There are no pharmacokinetic or pharmacodynamic data in allergic asthma or CSU patients with renal or hepatic impairment (see sections 4.2 and 4.4).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The safety of omalizumab has been studied in the cynomolgus monkey, since omalizumab binds to cynomolgus and human IgE with similar affinity. Antibodies to omalizumab were detected in some monkeys following repeated subcutaneous or intravenous administration. However, no apparent toxicity, such as immune complex-mediated disease or complement-dependent cytotoxicity, was seen. There was no evidence of an anaphylactic response due to mast-cell degranulation in cynomolgus monkeys.</p><p>&nbsp;</p><p>Chronic administration of omalizumab at dose levels of up to 250&nbsp;mg/kg (more than 14-fold the maximum allowable clinical dose of 17.5&nbsp;mg/kg according to the recommended dosing table) was well tolerated in non-human primates (both adult and juvenile animals), with the exception of a dose-related and age-dependent decrease in blood platelets, with a greater sensitivity in juvenile animals. The serum concentration required to attain a 50% drop in platelets from baseline in adult cynomolgus monkeys was roughly 4- to 20-fold higher than anticipated maximum clinical serum concentrations. In addition, acute haemorrhage and inflammation were observed at injection sites in cynomolgus monkeys.</p><p>&nbsp;</p><p>Formal carcinogenicity studies have not been conducted with omalizumab.</p><p>&nbsp;</p><p>In reproduction studies in cynomolgus monkeys, subcutaneous doses up to 75&nbsp;mg/kg (about 12-fold exposure ratio based on 28-day AUC values at 75&nbsp;mg/kg versus the clinical maximum dose) did not elicit maternal toxicity, embryotoxicity or teratogenicity when administered throughout organogenesis and did not elicit adverse effects on foetal or neonatal growth when administered throughout late gestation, delivery and nursing.</p><p>&nbsp;</p><p>Omalizumab is excreted in breast milk in cynomolgus monkeys. Milk levels of omalizumab were 1.5% of the maternal blood concentration.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sucrose</p><p>L-histidine hydrochloride</p><p>L-histidine</p><p>Polysorbate 20</p><p>Water for injections</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products&nbsp;except those mentioned in section&nbsp;6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years.

After reconstitution
The chemical and physical stability of the reconstituted medicinal product have been demonstrated for 8 hours at 2°C to 8°C and for 4 hours at 30°C.
From a microbiological point of view, the medicinal product should be used immediately after reconstitution. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 8 hours at 2°C to 8°C or 2 hours at 25°C.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C ‑ 8&deg;C).</p><p>Do not freeze.</p><p>For storage conditions after reconstitution of the medicinal product, see section&nbsp;6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Powder vial: Clear, colourless type&nbsp;I glass vial with a butyl rubber stopper and blue flip-off seal.</p><p>Solvent ampoule: Clear, colourless type&nbsp;I glass ampoule containing 2&nbsp;ml water for injections.</p><p>Pack containing 1&nbsp;vial of powder and 1&nbsp;ampoule of water for injections, and multipacks containing 4&nbsp;(4&nbsp;x&nbsp;1)&nbsp;vials of powder and 4&nbsp;(4&nbsp;x&nbsp;1)&nbsp;ampoules of water for injections or 10&nbsp;(10&nbsp;x&nbsp;1)&nbsp;vials of powder and 10&nbsp;(10&nbsp;x&nbsp;1)&nbsp;ampoules of water for injections.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Xolair 150&nbsp;mg powder for solution for injection is supplied in a single-use vial.</p><p>&nbsp;</p><p>From a microbiological point of view, the medicinal product should be used immediately after reconstitution (see section&nbsp;6.3).</p><p>&nbsp;</p><p>The lyophilised medicinal product takes 15‑20&nbsp;minutes to dissolve, although in some cases it may take longer. The fully reconstituted medicinal product will appear clear to slightly opalescent, colourless to pale brownish-yellow and may have a few small bubbles or foam around the edge of the vial. Because of the viscosity of the reconstituted medicinal product care must be taken to withdraw all of the medicinal product from the vial before expelling any air or excess solution from the syringe in order to obtain the 1.2&nbsp;ml.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                02/2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>